

# CITATION REPORT

List of articles citing

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease

DOI: 10.1523/jneurosci.21-02-00372.2001  
Journal of Neuroscience, 2001, 21, 372-81.

**Source:** <https://exaly.com/paper-pdf/32644413/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
915	Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. <b>2001</b> , 8, 1094-101		77
914	Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. <b>2001</b> , 159, 439-47		240
913	Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. <b>2001</b> , 22, 721-7		140
912	Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. <b>2001</b> , 22, 983-91		212
911	Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. <b>2001</b> , 56, 581-8		146
910	Anti-Aging Medicine LiteratureWatch. <b>2001</b> , 4, 157-179		
909	Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. <i>Journal of Neuroscience</i> , <b>2001</b> , 21, 4183-7	6.6	675
908	A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. <b>2001</b> , 414, 212-6		1228
907	Gridlock signalling pathway fashions the first embryonic artery. <b>2001</b> , 414, 216-20		448
906	Learning and memory in transgenic mice modeling Alzheimer's disease. <b>2001</b> , 8, 301-8		187
905	Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. <b>2001</b> , 15, 2454-62		122
904	Abeta immunization: moving Abeta peptide from brain to blood. <b>2001</b> , 98, 8931-2		21
903	A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. <b>2002</b> , 99, 4697-702		246
902	Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. <b>2002</b> , 277, 44670-6		272
901	Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. <b>2002</b> , 277, 22768-80		171
900	Analysis of Gene Expression by Nylon Membrane cDNA Arrays. <b>2002</b> , 133-147		
899	Cerebrospinal fluid shunting for Alzheimer's disease?. <b>2002</b> , 59, 1126-7		1

898	Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. <b>2002</b> , 277, 33012-7	50	
897	Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. <b>2002</b> , 16, 1138-40	215	
896	Serum creatinine levels correlate with plasma amyloid Beta protein. <b>2002</b> , 16, 187-90	57	
895	Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. <b>2002</b> , 41, 3128-36	98	
894	APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. <b>2002</b> , 41, 922-8	137	
893	Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. <b>2002</b> , 161, 1869-79	573	
892	Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery. <b>2002</b> , 160, 409-11	8	
891	Stable beta-secretase activity and presynaptic cholinergic markers during progressive central nervous system amyloidogenesis in Tg2576 mice. <b>2002</b> , 160, 731-8	55	
890	Insights into Abeta and presenilin from a canine model of human brain aging. <b>2002</b> , 9, 1-10	32	
889	Growth of beta-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. <b>2002</b> , 41, 6115-27	161	
888	Serum insulin-like growth factor I regulates brain amyloid-beta levels. <b>2002</b> , 8, 1390-7	441	
887	Apoptosis Techniques and Protocols. <b>2002</b> ,	3	
886	FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. <b>2002</b> , 23, 335-48	105	
885	Dietary enrichment counteracts age-associated cognitive dysfunction in canines. <b>2002</b> , 23, 737-45	112	
884	A safer vaccine for Alzheimer's disease?. <b>2002</b> , 23, 1001-8	39	
883	Generation of amyloid beta peptide with pyroglutamate at position 3 in primary cortical neurons. <b>2002</b> , 327, 25-8	21	
882	Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. <i>Journal of Neuroscience</i> , <b>2002</b> , 22, 7380-8	6.6	246
881	The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2002</b> , 22, 1858-67	6.6	600

880	Cerebrospinal fluid Ab40 and Ab42: natural course and clinical usefulness. <b>2002</b> , 7, d997		16
879	Reversible memory loss in a mouse transgenic model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2002</b> , 22, 6331-5	6.6	381
878	Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. <b>2002</b> , 54, 1603-13		52
877	Immunization for Alzheimer's disease. <b>2002</b> , 56, 135-142		8
876	Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites. <b>2002</b> , 441, 358-67		48
875	Does my mouse have Alzheimer's disease?. <b>2002</b> , 1, 142-55		100
874	Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. <b>2002</b> , 81, 229-36		208
873	Cerebrovascular effects of amyloid-beta peptides: mechanisms and implications for Alzheimer's dementia. <b>2003</b> , 23, 681-9		79
872	Transgenic mice expressing the betaAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination. <b>2003</b> , 977, 38-45		93
871	Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. <b>2003</b> , 74, 386-92		119
870	Aspartic proteases involved in Alzheimer's disease. <b>2003</b> , 4, 366-78		26
869	Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. <b>2003</b> , 84, 602-9		42
868	Study of Alzheimer's disease using transgenic mice: The mechanism of formation of brain A $\beta$ amyloid and neurofibrillary tangles. <b>2003</b> , 3, 154-158		
867	Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. <b>2003</b> , 10, 463-70		168
866	RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. <b>2003</b> , 9, 907-13		1085
865	A welcoming environment for amyloid plaques. <i>Nature Neuroscience</i> , <b>2003</b> , 6, 328-30	25.5	9
864	Alterations in cholinergic and non-cholinergic neurotransmitter receptor densities in transgenic Tg2576 mouse brain with beta-amyloid plaque pathology. <b>2003</b> , 21, 357-69		66
863	NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. <b>2003</b> , 112, 440-9		382

862	Divergent roles of GSK3 and CDK5 in APP processing. <b>2003</b> , 312, 922-9	110
861	Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. <b>2003</b> , 184, 510-20	168
860	Heat shock protein-90-induced microglial clearance of exogenous amyloid-beta1-42 in rat hippocampus in vivo. <b>2003</b> , 344, 87-90	35
859	Effect of PPF and ALCAR on the induction of NGF- and p75-mRNA and on APP processing in Tg2576 brain. <b>2003</b> , 43, 225-33	35
858	Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. <b>2003</b> , 24, 777-87	171
857	Peripheral cytokine release in Alzheimer patients: correlation with disease severity. <b>2003</b> , 24, 909-14	61
856	Accumulation of amyloid $\beta$ protein in Tg2576 mice. <b>2003</b> , 1252, 373-377	
855	Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. <b>2003</b> , 13, 246-53	185
854	BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. <b>2003</b> , 14, 81-8	143
853	Vaccines for Alzheimer's disease: how close are we?. <b>2003</b> , 17, 457-74	35
852	Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. <b>2003</b> , 60, 958-64	229
851	Blood-Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model. <b>2003</b> , 10, 463-470	231
850	The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. <b>2003</b> , 305, 864-71	130
849	Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. <b>2003</b> , 100, 4837-42	129
848	Genetic programming by the proteolytic fragments of the amyloid precursor protein: somewhere between confusion and clarity. <b>2003</b> , 14, 317-41	23
847	Genetic background regulates beta-amyloid precursor protein processing and beta-amyloid deposition in the mouse. <b>2003</b> , 12, 2949-56	67
846	Anti-Amyloidogenic Effect of Allium sativum in Alzheimer's Transgenic Model Tg2576. <b>2003</b> , 3, 95-107	24
845	The peptide KLVFF-K(6) promotes beta-amyloid(1-40) protofibril growth by association but does not alter protofibril effects on cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). <b>2003</b> , 64, 1160-8	22

844	Emergence of a cue strategy preference on the water maze task in aged C57B6 x SJL F1 hybrid mice. <b>2003</b> , 10, 520-4		40
843	Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. <b>2003</b> , 278, 4458-66		67
842	The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. <b>2003</b> , 278, 47025-9		60
841	Secretion and accumulation of Abeta by brain vascular smooth muscle cells from AbetaPP-Swedish transgenic mice. <b>2003</b> , 62, 685-96		40
840	Abeta levels in serum, CSF and brain, and cognitive deficits in APP + PS1 transgenic mice. <b>2003</b> , 14, 163-6		23
839	Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 29-33	6.6	291
838	Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 5645-9	6.6	156
837	Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma <sup>-/-</sup> knock-out mice. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 8532-8	6.6	191
836	[Development of animal models for therapy of Alzheimer's disease]. <b>2003</b> , 40, 27-9		
835	PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 8989-9003	6.6	163
834	The Amyloid Hypothesis and the clearance and degradation of Alzheimer's beta-peptide. <b>2004</b> , 6, 303-14		19
833	[Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives]. <b>2004</b> , 72, 204-19		2
832	RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. <b>2004</b> , 35, 2628-31		311
831	Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-LY-411575. <b>2004</b> , 303, 49-55		125
830	Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. <i>Journal of Neuroscience</i> , <b>2004</b> , 24, 4535-40	6.6	179
829	Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. <b>2004</b> , 13, 1225-40		259
828	Active immunization of mice with an Abeta-Hsp70 vaccine. <b>2004</b> , 1, 20-8		18
827	Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. <b>2004</b> , 279, 20296-306		261

826	The neuronal adaptor protein X11beta reduces amyloid beta-protein levels and amyloid plaque formation in the brains of transgenic mice. <b>2004</b> , 279, 49099-104		58
825	Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice. <b>2004</b> , 279, 52535-42		34
824	Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2004</b> , 24, 3801-9	6.6	287
823	Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. <b>2004</b> , 63, 828-31		100
822	Clearing amyloid through the blood-brain barrier. <b>2004</b> , 89, 807-11		298
821	In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. <b>2004</b> , 89, 1409-16		100
820	Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. <b>2004</b> , 37, 129-36		143
819	Neurovascular regulation in the normal brain and in Alzheimer's disease. <b>2004</b> , 5, 347-60		1662
818	Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. <b>2004</b> , 24, 334-42		111
817	Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. <b>2004</b> , 90, 758-64		126
816	Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. <b>2004</b> , 1012, 29-41		97
815	Transgenic BACE expression in mouse neurons accelerates amyloid plaque pathology. <b>2004</b> , 111, 413-25		39
814	Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. <b>2004</b> , 138, 233-42		48
813	Characterization of chronic low-level proteasome inhibition on neural homeostasis. <b>2003</b> , 86, 489-97		109
812	Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. <b>2004</b> , 55, 801-14		280
811	High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. <b>2004</b> , 78, 880-91		64
810	Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. <i>Journal of Neuroscience</i> , <b>2004</b> , 24, 11120-6	6.6	249
809	Obesity-related leptin regulates Alzheimer's Abeta. <b>2004</b> , 18, 1870-8		241

808	Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. <i>Journal of Neuroscience</i> , <b>2004</b> , 24, 3592-9	6.6	377
807	Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. <b>2004</b> , 56, 670-6		155
806	Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. <b>2004</b> , 18, 902-4		502
805	Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis. <i>Journal of Neuroinflammation</i> , <b>2004</b> , 1, 21	10.1	64
804	Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. <b>2004</b> , 43, 6899-908		263
803	Abeta N-terminal-end specific antibody reduced beta-amyloid in Alzheimer-model mice. <b>2004</b> , 325, 384-7		20
802	Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD. <b>2004</b> , 25, 1175-85		20
801	The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. <b>2004</b> , 25, 1315-21		167
800	LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. <b>2004</b> , 43, 333-44		661
799	The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. <b>2004</b> , 44, 227-38		220
798	Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. <b>2004</b> , 125, 1009-17		36
797	Building a more perfect beast: APP transgenic mice with neuronal loss. <b>2004</b> , 164, 1143-6		23
796	Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. <b>2004</b> , 165, 2197-206		144
795	Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. <b>2004</b> , 165, 1809-17		194
794	Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. <b>2004</b> , 15, 188-95		98
793	Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. <b>2004</b> , 17, 500-6		88
792	Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. <b>2004</b> , 17, 516-23		32
791	Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice. <b>2004</b> , 368, 285-9		30



790	Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. <b>2004</b> , 25, 861-71	100
789	Soluble Abeta homeostasis in AD and DS: impairment of anti-amyloidogenic protection by lipoproteins. <b>2004</b> , 25, 833-41	26
788	Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. <b>2004</b> , 22, 475-84	142
787	Biophysical alterations of hippocampal pyramidal neurons in learning, ageing and Alzheimer's disease. <b>2004</b> , 3, 383-406	72
786	Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. <b>2004</b> , 13, 159-70	1073
785	BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. <b>2004</b> , 41, 27-33	457
784	Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. <b>2004</b> , 562, 16-21	32
783	Decreased level of brain acetylcholine and memory disturbance in APPsw mice. <b>2004</b> , 25, 483-90	38
782	Intramaze and extramaze cue processing in adult APPSWE Tg2576 transgenic mice. <b>2004</b> , 118, 1184-95	22
781	Alzheimer's Disease: Current and Future Treatments. <b>2005</b> , 329-354	1
780	Application of a non-linear image registration algorithm to quantitative analysis of T2 relaxation time in transgenic mouse models of AD pathology. <b>2005</b> , 144, 91-7	18
779	Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent. <b>2005</b> , 1057, 327-36	23
778	Effects of Abeta1-42 fibrils and of the tetrapeptide Pr-IIGL on the phosphorylation state of the tau-protein and on the alpha7 nicotinic acetylcholine receptor in vitro. <b>2005</b> , 21, 879-88	8
777	Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. <b>2005</b> , 11, 545-50	254
776	Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. <b>2005</b> , 11, 959-65	233
775	Amyloid-beta in Alzheimer's disease: the horse or the cart? Pathogenic or protective?. <b>2005</b> , 86, 133-8	48
774	Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. <b>2005</b> , 69, 689-98	93
773	PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. <b>2005</b> , 32, 593-600	108

772	What is the dominant Abeta species in human brain tissue? A review. <b>2005</b> , 7, 29-41		39
771	Role of melatonin in neurodegenerative diseases. <b>2005</b> , 7, 293-318		159
770	Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. <b>2005</b> , 2, e355		157
769	Memory deficits correlating with acetylcholinesterase splice shift and amyloid burden in doubly transgenic mice. <b>2005</b> , 2, 291-300		53
768	Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. <b>2005</b> , 14, 447-60		58
767	IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 11495-503	6.6	198
766	Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. <b>2005</b> , 19, 255-7		182
765	Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease. <b>2005</b> , 14, 1385-409		51
764	Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. <b>2005</b> , 19, 659-61		205
763	Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 629-36	6.6	278
762	NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 1769-77	6.6	200
761	Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. <b>2005</b> , 312, 399-406		71
760	Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. <b>2005</b> , 312, 635-43		156
759	Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 5217-24	6.6	386
758	Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities. <b>2005</b> , 25, 278-93		42
757	Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 8898-902	6.6	189
756	Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. <b>2005</b> , 30, 1111-20		90
755	Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. <b>2005</b> , 280, 5892-901		1668

754	Selective Reductions in Plasma A $\beta$ 1-42 in Healthy Elderly Subjects During Longitudinal Follow-Up: A Preliminary Report. <b>2005</b> , 13, 914-917		7
753	Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-Valine]. <b>2005</b> , 313, 902-8		97
752	Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease. <b>2005</b> , 156, 225-32		104
751	Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice. <b>2005</b> , 160, 344-55		67
750	Neurovascular mechanisms of Alzheimer's neurodegeneration. <b>2005</b> , 28, 202-8		732
749	Part of membrane-bound Abeta exists in rafts within senile plaques in Tg2576 mouse brain. <b>2005</b> , 26, 409-18		44
748	Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice. <b>2005</b> , 26, 1167-75		20
747	Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. <b>2005</b> , 26, 1235-44		270
746	Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. <b>2005</b> , 47, 191-199		463
745	Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. <b>2005</b> , 48, 913-22		882
744	Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. <b>2005</b> , 132, 73-86		53
743	Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , <b>2005</b> , 2, 9	10.1	194
742	Kinetics of inhibition of beta-amyloid aggregation by transthyretin. <b>2006</b> , 45, 15702-9		64
741	Prevention and Treatment of Age-related Diseases. <b>2006</b> ,		2
740	Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. <i>Journal of Neuroscience</i> , <b>2006</b> , 26, 10939-48	6.6	269
739	CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. <i>Journal of Neuroinflammation</i> , <b>2006</b> , 3, 3	10.1	20
738	Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. <b>2006</b> , 249, 110-4		38
737	Effects of lipids and aging on the neurotoxicity and neuronal loss caused by intracerebral injections of the amyloid-beta peptide in the rat. <b>2006</b> , 197, 41-55		20

736	Evaluation of white matter integrity in ex vivo brains of amyloid plaque-bearing APPsw transgenic mice using magnetic resonance diffusion tensor imaging. <b>2006</b> , 199, 408-15	34
735	Emerging evidence for the neuroprotective role of alpha-synuclein. <b>2006</b> , 200, 1-7	25
734	Soluble Abeta and cognitive function in aged F-344 rats and Tg2576 mice. <b>2006</b> , 173, 62-75	17
733	Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. <b>2006</b> , 54, 235-53	82
732	Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. <b>2006</b> , 24, 149-56	56
731	Type-specific evolution of amyloid plaque and angiopathy in APPsw mice. <b>2006</b> , 395, 37-41	12
730	Bosentan preserves endothelial function in mice overexpressing APP. <b>2006</b> , 27, 446-50	21
729	Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease?. <b>2006</b> , 27, 1618-31	109
728	Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment. <b>2006</b> , 27, 904-5	85
727	Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. <b>2006</b> , 24, 2824-34	16
726	Soluble amyloid-beta in the brain: the scarlet pimpernel. <b>2006</b> , 9, 127-32	8
725	Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42. <b>2006</b> , 67, 830-3	41
724	In search of the molecular basis of memory loss in Alzheimer disease. <b>2006</b> , 20, 200-1	3
723	Metallothionein-3 is a component of a multiprotein complex in the mouse brain. <b>2006</b> , 231, 1500-6	30
722	Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. <b>2006</b> , 23, 251-60	221
721	Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors. <b>2006</b> , 23, 2035-47	69
720	Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. <b>2006</b> , 24, 2530-42	81
719	Progressive cognitive decline in a transgenic mouse model of Alzheimer's disease overexpressing mutant hAPPswe. <b>2006</b> , 5, 249-56	24

718	A specific amyloid-beta protein assembly in the brain impairs memory. <b>2006</b> , 440, 352-7	2406
717	The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. <b>2006</b> , 16, 2219-23	22
716	Natural secretory products of human neural and microvessel endothelial cells: Implications in pathogenic "spreading" and Alzheimer's disease. <b>2006</b> , 34, 181-92	35
715	Metallothionein-3 and neuronal nitric oxide synthase levels in brains from the Tg2576 mouse model of Alzheimer's disease. <b>2006</b> , 283, 129-37	25
714	Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2006</b> , 112, 163-74	14-3 73
713	Amyloid-beta, BACE, and oxidative stress in Alzheimer's disease, a commentary on "The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression". <b>2006</b> , 41, 188-9	5
712	Enhanced accumulation of tau in doubly transgenic mice expressing mutant betaAPP and presenilin-1. <b>2006</b> , 1094, 192-9	27
711	Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. <b>2006</b> , 5, 655-60	364
710	Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. <b>2006</b> , 24, 516-24	525
709	Lack of neprilysin suffices to generate murine amyloid-like deposits in the brain and behavioral deficit in vivo. <b>2006</b> , 84, 1871-8	65
708	Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. <b>2006</b> , 59, 512-9	1009
707	Genetically modified mice models for Alzheimer's disease. <b>2006</b> , 6, 609-27	13
706	Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. <b>2006</b> , 17, 429-54	25
705	The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. <b>2006</b> , 6, 597-608	96
704	Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV7171-CT100 transgenic mice, an Alzheimer's disease model. <b>2006</b> , 20, 729-31	193
703	Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. <b>2006</b> , 63, 936-9	105
702	Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. <b>2006</b> , 20, 2576-8	97
701	A novel phospholipid derivative of indomethacin, DP-155 [mixture of 1-steroyl and 1-palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosphatidyl [corrected] choline], shows superior safety and similar efficacy in reducing brain amyloid beta in an Alzheimer's disease model. <b>2006</b> , 318, 1218-56	32

700	AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice. <b>2006</b> , 103, 3410-5		175
699	Abeta40 inhibits amyloid deposition in vivo. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 627-33	6.6	280
698	Abeta1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases. <b>2007</b> , 120, 279-88		81
697	G-CSF rescues the memory impairment of animal models of Alzheimer's disease. <b>2007</b> , 204, 1273-80		117
696	Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 8628-35	6.6	139
695	Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. <b>2007</b> , 282, 22707-20		86
694	Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 10957-68	6.6	246
693	Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?. <b>2007</b> , 4, 253-62		74
692	Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease. <b>2007</b> , 4, 562-7		22
691	Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. <b>2007</b> , 130, 2310-9		146
690	1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. <b>2007</b> , 323, 822-30		74
689	The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. <b>2007</b> , 282, 552-9		78
688	Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. <b>2007</b> , 104, 8167-72		101
687	Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. <b>2007</b> , 282, 22376-86		83
686	Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 12721-31	6.6	81
685	Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. <b>2007</b> , 117, 3393-402		235
684	[Actin cytoskeletal abnormality in Alzheimer's disease]. <b>2007</b> , 130, 358-61		
683	Acide docosahexaïque et maladie d'Alzheimer : des raisons d'être ? <b>2007</b> , 14, 16-24		

682	Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. <b>2007</b> , 66, 469-80	57
681	Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. <b>2007</b> , 28, 213-25	130
680	Intact spatial learning in adult Tg2576 mice. <b>2007</b> , 28, 440-6	24
679	Early discrimination reversal learning impairment and preserved spatial learning in a longitudinal study of Tg2576 APPsw mice. <b>2007</b> , 28, 1248-57	38
678	The odour span task: a novel paradigm for assessing working memory in mice. <b>2007</b> , 52, 634-45	51
677	Intrahippocampal administration of A beta(1-40) impairs spatial learning and memory in hyperglycemic mice. <b>2007</b> , 87, 483-94	38
676	Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. <b>2007</b> , 88, 217-24	113
675	Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. <b>2007</b> , 361, 800-4	10
674	Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. <b>2007</b> , 51, 391-7	31
673	The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease. <b>2007</b> , 427, 127-31	99
672	The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. <b>2007</b> , 428, 53-8	32
671	Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. <b>2007</b> , 581, 475-8	74
670	In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. <b>2007</b> , 35, 1401-8	128
669	Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. <b>2007</b> , 64, 354-62	343
668	Abeta Peptide and Alzheimer's Disease. <b>2007</b> ,	1
667	Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. <b>2007</b> , 21, 2135-48	125
666	Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization. <b>2007</b> , 21, 3184-96	37
665	Increased amyloid beta protein levels in children and adolescents with Down syndrome. <b>2007</b> , 254, 22-7	59

664	Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. <b>2007</b> , 61, 446-53	67
663	Accumulation of triosephosphate isomerase, with sequence homology to Beta amyloid peptides, in vessel walls of the newborn piglet hippocampus. <b>2007</b> , 70, 648-55	4
662	Enhanced accumulation of phosphorylated alpha-synuclein in double transgenic mice expressing mutant beta-amyloid precursor protein and presenilin-1. <b>2007</b> , 85, 2246-52	17
661	Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Aβ levels. <b>2007</b> , 2, 11	56
660	Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. <b>2007</b> , 7, 605-616	106
659	DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy. <b>2007</b> , 13, 260-77	28
658	Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. <b>2007</b> , 102, 1095-104	490
657	Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Aβ antibodies. <b>2007</b> , 8, 22	37
656	Plaques, tangles, and memory loss in mouse models of neurodegeneration. <b>2007</b> , 37, 79-100	113
655	Mechanisms of amyloid plaque pathogenesis. <i>Acta Neuropathologica</i> , <b>2007</b> , 114, 551-71	14.3 80
654	Intranasal tat alters gene expression in the mouse brain. <b>2007</b> , 2, 87-92	10
653	beta-Secretase as a therapeutic target for Alzheimer's disease. <b>2008</b> , 5, 399-408	158
652	Deglycosylated anti-Aβ antibody dose-response effects on pathology and memory in APP transgenic mice. <b>2008</b> , 3, 187-97	18
651	Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. <b>2008</b> , 10, 195-207	28
650	Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies. <b>2001</b> , 79, 595-605	261
649	Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. <b>2008</b> , 18, 1031-6	81
648	Quartz crystal microbalance analysis of growth kinetics for aggregation intermediates of the amyloid-beta protein. <b>2008</b> , 378, 15-24	54
647	Glutamyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease-like pathology. <b>2008</b> , 14, 1106-11	275



646	Macrophage colony stimulating factor is associated with excretion of amyloid- $\beta$ peptides from cerebrospinal fluid to peripheral blood. <b>2008</b> , 8, 188-195	3
645	Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. <b>2008</b> , 106, 1225-36	58
644	Lipid peroxidation up-regulates BACE1 expression in vivo: a possible early event of amyloidogenesis in Alzheimer's disease. <b>2008</b> , 107, 197-207	83
643	Peripheral elevation of IGF-1 fails to alter Abeta clearance in multiple in vivo models. <b>2008</b> , 75, 1093-103	25
642	Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. <b>2008</b> , 1219, 169-79	23
641	Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. <b>2008</b> , 1226, 209-17	59
640	Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis. <b>2008</b> , 585, 109-18	47
639	Significant structural but not physiological changes in cortical neurons of 12-month-old Tg2576 mice. <b>2008</b> , 32, 309-18	31
638	Prion infection of mice transgenic for human APPSwe: increased accumulation of cortical formic acid extractable Abeta(1-42) and rapid scrapie disease development. <b>2008</b> , 26, 821-4	14
637	Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). <b>2008</b> , 448, 217-20	11
636	ApoE promotes the proteolytic degradation of Abeta. <b>2008</b> , 58, 681-93	680
635	Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. <b>2008</b> , 151, 745-9	136
634	Effects of oral aluminum exposure on behavior and neurogenesis in a transgenic mouse model of Alzheimer's disease. <b>2008</b> , 214, 293-300	75
633	Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. <b>2008</b> , 1782, 549-58	60
632	Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. <b>2008</b> , 173, 762-72	49
631	Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. <b>2008</b> , 70, 596-606	72
630	Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. <b>2008</b> , 47, 7405-13	86
629	Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. <b>2008</b> , 105, 14052-7	193

628	Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. <b>2008</b> , 105, 1347-52		251
627	Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 13542-50	6.6	109
626	Detecting Alzheimer disease before it happens: The key to prevention?. <b>2008</b> , 71, 78-9		3
625	Memapsin 2 (beta-secretase) inhibitors: drug development. <b>2008</b> , 5, 121-31		51
624	An increase in Abeta42 in the prefrontal cortex is associated with a reversal-learning impairment in Alzheimer's disease model Tg2576 APPsw mice. <b>2008</b> , 5, 385-91		22
623	In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. <b>2008</b> , 324, 957-69		95
622	Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study. <b>2008</b> , 65, 256-63		77
621	Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. <b>2008</b> , 17, 3474-86		59
620	PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. <b>2008</b> , 26, 378-83		84
619	Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. <b>2008</b> , 131, 651-64		181
618	Amyloid-associated depression: a prodromal depression of Alzheimer disease?. <b>2008</b> , 65, 542-50		120
617	Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2008</b> , 28, 6388-92	6.6	302
616	Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. <b>2008</b> , 65, 906-12		74
615	Spatial memory impairment without apoptosis induced by the combination of beta-amyloid oligomers and cerebral ischemia is related to decreased acetylcholine release in rats. <b>2008</b> , 106, 84-91		23
614	Neuroimaging in dementia: in vivo amyloid imaging. <b>2008</b> , 215, 119-24		5
613	Chapter 5.5 Transgenic mouse models of Alzheimer's disease and episodic-like memory. <b>2008</b> , 18, 553-573		1
612	Limited clearance of pre-existing amyloid plaques after intracerebral injection of Abeta antibodies in two mouse models of Alzheimer disease. <b>2008</b> , 67, 30-40		17
611	Plasma biomarkers of Alzheimer's disease. <b>2008</b> , 21, 260-7		27

610	Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-beta. <b>2008</b> , 14, 161-73		10
609	nELAV proteins alteration in Alzheimer's disease brain: a novel putative target for amyloid-beta reverberating on AbetaPP processing. <b>2009</b> , 16, 409-19		50
608	Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease. <b>2009</b> , 18, 89-102		21
607	Amyloid-beta42 plasma levels are elevated in amnesic mild cognitive impairment. <b>2009</b> , 18, 267-71		20
606	X11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice. <b>2009</b> , 18, 4492-500		25
605	Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. <b>2009</b> , 106, 4501-6		102
604	Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 8805-15	6.6	163
603	Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. <b>2009</b> , 284, 32895-905		136
602	Serum beta-amyloid correlates with neuropsychological impairment. <b>2009</b> , 16, 203-18		15
601	Cool with plaques and tangles. <b>2009</b> , 360, 2357-9		17
600	New perspectives for the diagnosis of Alzheimer's disease. <b>2009</b> , 4, 160-81		11
599	Detection of Amyloid-beta aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease?. <b>2009</b> , 6, 285-9		20
598	Suppression of amyloid deposition leads to long-term reductions in Alzheimer's pathologies in Tg2576 mice. <i>Journal of Neuroscience</i> , <b>2009</b> , 29, 4964-71	6.6	27
597	Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease. <b>2009</b> , 35, 426-32		182
596	Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. <b>2010</b> , 58, 300-14		136
595	Recurrent systemic infections with <i>Streptococcus pneumoniae</i> do not aggravate the course of experimental neurodegenerative diseases. <b>2010</b> , 88, 1124-36		11
594	A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. <i>Acta Neuropathologica</i> , <b>2009</b> , 118, 505-17	14.3	37
593	Neuroinflammation and memory: the role of prostaglandins. <b>2009</b> , 40, 15-32		118

592	Neuroimaging outcomes in clinical trials in Alzheimer's disease. <b>2009</b> , 13, 209-12	17
591	Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. <b>2009</b> , 4, 19	49
590	Amyloid beta and impairment in multiple memory systems in older transgenic APP TgCRND8 mice. <b>2009</b> , 8, 676-84	19
589	Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. <b>2009</b> , 276, 995-1006	66
588	Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate. <b>2009</b> , 36, 1099-103	1
587	Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease. <b>2009</b> , 19, 48-57	28
586	CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. <b>2009</b> , 156, 982-93	73
585	Behavioral stress accelerates plaque pathogenesis in the brain of Tg2576 mice via generation of metabolic oxidative stress. <b>2009</b> , 108, 165-75	106
584	Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. <b>2009</b> , 109, 303-15	66
583	Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. <b>2009</b> , 110, 791-800	43
582	Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model. <b>2009</b> , 382, 149-52	6
581	Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice. <b>2009</b> , 30, 272-83	66
580	Progressive impairment in olfactory working memory in a mouse model of Mild Cognitive Impairment. <b>2009</b> , 30, 1430-43	48
579	A highly insoluble state of Abeta similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. <b>2009</b> , 30, 1393-405	62
578	DNA base excision repair activities in mouse models of Alzheimer's disease. <b>2009</b> , 30, 2080-1	20
577	Asymmetric expression patterns of brain transthyretin in normal mice and a transgenic mouse model of Alzheimer's disease. <b>2009</b> , 159, 638-46	17
576	Synaptic transmission is impaired prior to plaque formation in amyloid precursor protein-overexpressing mice without altering behaviorally-correlated sharp wave-ripple complexes. <b>2009</b> , 162, 1081-90	41
575	Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. <b>2009</b> , 27, 517-23	33

574	Ameliorative effects of yokukansan, a traditional Japanese medicine, on learning and non-cognitive disturbances in the Tg2576 mouse model of Alzheimer's disease. <b>2009</b> , 122, 157-62		62
573	[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. <b>2009</b> , 54, 347-57		72
572	Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. <b>2009</b> , 55, 243-52		54
571	Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. <b>2009</b> , 30, 1936-48		102
570	Beta amyloid oligomers and fibrils stimulate differential activation of primary microglia. <i>Journal of Neuroinflammation</i> , <b>2009</b> , 6, 1	10.1	169
569	Differential modification of Cys10 alters transthyretin's effect on beta-amyloid aggregation and toxicity. <b>2009</b> , 22, 479-88		10
568	Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease. <b>2009</b> , 106, 13576-81		160
567	Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. <b>2009</b> , 220, 171-6		59
566	Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. <b>2009</b> , 73, 847-53		111
565	Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. <b>2009</b> , 18, 459-69		82
564	The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. <b>2010</b> , 69, 777-88		43
563	Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. <b>2010</b> , 69, 253-61		32
562	Plasma $\beta$ amyloid and cognitive decline. <b>2010</b> , 67, 1485-90		68
561	Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. <b>2010</b> , 20, 637-46		54
560	[Animal models of Alzheimer's disease for preclinical research.]. <b>2010</b> , 136, 6-10		
559	Elevation of {beta}-amyloid 1-42 autoantibodies in the blood of amnesic patients with mild cognitive impairment. <b>2010</b> , 67, 867-72		26
558	Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2010</b> , 119, 523-41	14.3	267
557	Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. <b>2010</b> , 214, 201-18		35

556	A serial analysis of gene expression profile of the Alzheimer's disease Tg2576 mouse model. <b>2010</b> , 17, 360-79	43
555	Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. <b>2010</b> , 5, 133-42	11
554	Beta-amyloid controls altered Reelin expression and processing in Alzheimer's disease. <b>2010</b> , 37, 682-91	42
553	Vitamin C deficiency increases basal exploratory activity but decreases scopolamine-induced activity in APP/PSEN1 transgenic mice. <b>2010</b> , 94, 543-52	24
552	Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. <b>2010</b> , 45, 195-201	60
551	Mice expressing the Swedish APP mutation on a 129 genetic background demonstrate consistent behavioral deficits and pathological markers of Alzheimer's disease. <b>2010</b> , 1311, 136-47	30
550	Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition. <b>2010</b> , 1315, 137-49	67
549	Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome. <b>2010</b> , 25, 202-7	34
548	Animal Models to Study the Biology of Amyloid- $\beta$ Protein Misfolding in Alzheimer Disease. <b>2010</b> , 213-229	
547	Amyloid-beta oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. <b>2010</b> , 88, 2923-32	75
546	Animal models of amyloid-beta-related pathologies in Alzheimer's disease. <b>2010</b> , 277, 1389-409	74
545	Limited expression of heparan sulphate proteoglycans associated with A $\beta$ deposits in the APP <sup>swe</sup> /PS1 <sup>dE9</sup> mouse model for Alzheimer's disease. <b>2010</b> , 36, 478-86	9
544	Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. <b>2010</b> , 20, 794-802	76
543	Retinoic acid receptor- $\beta$ signalling antagonizes both intracellular and extracellular amyloid- $\beta$ production and prevents neuronal cell death caused by amyloid- $\beta$ <b>2010</b> , 32, 1246-55	58
542	Expression of the Neuronal Adaptor Protein X11 $\beta$ Protects Against Memory Dysfunction in a Transgenic Mouse Model of Alzheimer's Disease. <b>2010</b> , 20, 31-36	10
541	Severe motor neuron degeneration in the spinal cord of the Tg2576 mouse model of Alzheimer disease. <b>2010</b> , 21, 263-76	41
540	Ablation of the locus coeruleus increases oxidative stress in tg-2576 transgenic but not wild-type mice. <b>2010</b> , 2010, 864625	6
539	Anesthetics promoting in vitro A $\beta$ PP metabolism and amyloid- $\beta$ toxicity. <b>2010</b> , 22 Suppl 3, 21-6	2

538	Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice. <b>2010</b> , 19, 691-704		97
537	Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice. <b>2010</b> , 335, 580-8		21
536	Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 11251-8	6.6	20
535	Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 7516-27	6.6	100
534	Targeting S100B in Cerebral Ischemia and in Alzheimer's Disease. <b>2010</b> , 2010,		20
533	Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease. <b>2010</b> , 333, 110-9		39
532	Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice. <b>2010</b> , 42, 386-94		135
531	A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 4845-56	6.6	301
530	AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. <b>2010</b> , 285, 9100-13		464
529	Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?. <b>2010</b> , 21, 1089-99		56
528	Amyloid- $\beta$ as a modulator of synaptic plasticity. <b>2010</b> , 22, 741-63		170
527	Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 2442-53	6.6	149
526	Olfactory dysfunction correlates with amyloid-beta burden in an Alzheimer's disease mouse model. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 505-14	6.6	203
525	Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. <i>Journal of Neuroscience</i> , <b>2010</b> , 30, 13110-5	6.6	119
524	Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. <b>2010</b> , 4, 81-9		20
523	Widespread protein aggregation as an inherent part of aging in <i>C. elegans</i> . <b>2010</b> , 8, e1000450		431
522	Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. <b>2010</b> , 67, 513-21		129
521	Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. <b>2010</b> , 68, 922-9		52

520	Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. <b>2010</b> , 81, 1123-7	61
519	Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. <b>2010</b> , 77, 715-23	241
518	Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer's disease. <b>2010</b> , 469, 273-7	10
517	Pyroglutamate-A $\beta$ role in the natural history of Alzheimer's disease. <b>2010</b> , 42, 1915-8	59
516	Neurogenesis in mouse models of Alzheimer's disease. <b>2010</b> , 1802, 872-80	67
515	In-vivo visualization of key molecular processes involved in Alzheimer's disease pathogenesis: Insights from neuroimaging research in humans and rodent models. <b>2010</b> , 1802, 373-88	16
514	Murine models of Alzheimer's disease and their use in developing immunotherapies. <b>2010</b> , 1802, 847-59	55
513	Effect size of reference memory deficits in the Morris water maze in Tg2576 mice. <b>2010</b> , 212, 115-20	28
512	Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice. <b>2010</b> , 31, 2058-68	29
511	Integrating ADNI results into Alzheimer's disease drug development programs. <b>2010</b> , 31, 1481-92	44
510	ADDLs and the signaling web that leads to Alzheimer's disease. <b>2010</b> , 59, 230-42	90
509	Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing. <b>2010</b> , 171, 1091-101	20
508	Low concentrations of anti-A $\beta$ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. <b>2010</b> , 21, 1569-76	7
507	Lifespan daily locomotor activity rhythms in a mouse model of amyloid-induced neuropathology. <b>2010</b> , 27, 1159-77	23
506	Meta-analysis of plasma amyloid- $\beta$ levels in Alzheimer's disease. <b>2011</b> , 26, 365-75	95
505	Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. <b>2011</b> , 13, e21	134
504	Beta-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. <b>2011</b> , 25, 775-84	93
503	Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer's disease. <b>2011</b> , 216, 77-83	33



502	Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. <b>2011</b> , 216, 255-61	77
501	Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. <b>2011</b> , 216, 408-13	52
500	Activity-induced dendrite and dendritic spine development in human amyloid precursor protein transgenic mice. <b>2011</b> , 29, 107-14	1
499	Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease. <b>2011</b> , 32, 1079-89	55
498	Liver X receptor activation restores memory in aged AD mice without reducing amyloid. <b>2011</b> , 32, 1262-72	101
497	Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. <b>2011</b> , 32, 31-41	146
496	Efficacy of PPAR- $\alpha$ agonist pioglitazone in mild Alzheimer disease. <b>2011</b> , 32, 1626-33	275
495	Early-onset dysfunction of retrosplenial cortex precedes overt amyloid plaque formation in Tg2576 mice. <b>2011</b> , 174, 71-83	13
494	Yokukansan, a traditional Japanese medicine, ameliorates memory disturbance and abnormal social interaction with anti-aggregation effect of cerebral amyloid $\beta$ proteins in amyloid precursor protein transgenic mice. <b>2011</b> , 180, 305-13	54
493	Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin. <b>2011</b> , 197, 358-68	22
492	PET applications in animal models of neurodegenerative and neuroinflammatory disorders. <b>2012</b> , 11, 45-64	3
491	Biomarkers in Alzheimer's disease drug development. <b>2011</b> , 7, e13-44	87
490	Passive (amyloid- $\beta$ ) immunotherapy attenuates monoaminergic axonal degeneration in the A $\beta$ PPswe/PS1dE9 mice. <b>2011</b> , 23, 271-9	12
489	Anti-A $\beta$ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. <b>2011</b> , 6, e25788	134
488	A longitudinal study of behavioral deficits in an A $\beta$ PP transgenic mouse model of Alzheimer's disease. <b>2011</b> , 25, 231-43	44
487	Neuropathology and amyloid- $\beta$ spectrum in a bapineuzumab immunotherapy recipient. <b>2011</b> , 24, 315-25	24
486	Effects of heparin and enoxaparin on APP processing and A $\beta$ production in primary cortical neurons from Tg2576 mice. <b>2011</b> , 6, e23007	18
485	Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: an insight into the pathogenic effects of amyloid- $\beta$ <b>2011</b> , 23, 195-206	76

484	In vivo human amyloid imaging. <b>2011</b> , 8, 366-72		30
483	Aggregation state and neurotoxic properties of alzheimer $\beta$ -amyloid peptide. <b>2011</b> , 12, 235-57		14
482	Amyloidopathy in the Eye of Alzheimer's Disease. <b>2011</b> , s5,		1
481	Environmental enrichment compensates for the effects of stress on disease progression in Tg2576 mice, an Alzheimer's disease model. <b>2011</b> , 119, 1282-93		22
480	Chronic treatment with a novel $\beta$ -secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease. <b>2011</b> , 163, 375-89		50
479	Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. <i>Nature Neuroscience</i> , <b>2011</b> , 14, 69-76	25.5	401
478	Roles of p75NTR in the pathogenesis of Alzheimer's disease: a novel therapeutic target. <b>2011</b> , 82, 1500-9		45
477	Anti-TNF $\alpha$ reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. <b>2011</b> , 1368, 239-47		147
476	Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. <b>2011</b> , 1371, 161-70		75
475	Which memory task for my mouse? A systematic review of spatial memory performance in the Tg2576 Alzheimer's mouse model. <b>2011</b> , 26, 105-26		78
474	Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, anti- $\beta$ Ab2, in nonclinical species. <b>2011</b> , 28, 1696-706		41
473	Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. <i>Acta Neuropathologica</i> , <b>2011</b> , 121, 431-43	14.3	232
472	Metallothionein and brain inflammation. <b>2011</b> , 16, 1103-13		45
471	Pathway-specific alteration of synaptic plasticity in Tg2576 mice. <b>2011</b> , 32, 197-201		19
470	Beta-amyloid increases the expression level of ATBF1 responsible for death in cultured cortical neurons. <b>2011</b> , 6, 47		17
469	Downregulation of CREB expression in Alzheimer's brain and in A $\beta$ -treated rat hippocampal neurons. <b>2011</b> , 6, 60		151
468	Preclinical study of dimebon on $\beta$ -amyloid-mediated neuropathology in Alzheimer's disease. <b>2011</b> , 6, 7		23
467	Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy. <b>2011</b> , 6, 86		39

466	Peripheral reduction of $\beta$ -amyloid is sufficient to reduce brain $\beta$ -amyloid: implications for Alzheimer's disease. <b>2011</b> , 89, 808-14		78
465	The relationship between plasma amyloid- $\beta$ peptides and the medial temporal lobe in the homebound elderly. <b>2011</b> , 26, 593-601		10
464	Amyloid- $\beta$ 42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. <b>2011</b> , 196, 51-9		36
463	Diet intervention and cerebrospinal fluid biomarkers in amnesic mild cognitive impairment. <b>2011</b> , 68, 743-52		100
462	Genetic mouse models of neurodegenerative diseases. <b>2011</b> , 100, 419-82		33
461	Systems biology--biomedical modeling. <b>2011</b> , 4, tr2		19
460	Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule $\beta$ -secretase inhibitors. <b>2011</b> , 339, 922-34		21
459	PKC $\beta$ activation prevents synaptic loss, A $\beta$ elevation, and cognitive deficits in Alzheimer's disease transgenic mice. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 630-43	6.6	154
458	Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. <b>2011</b> , 286, 33489-500		42
457	Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A $\beta$ is induced by pyroglutamate-A $\beta$ formation. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 12790-801	6.6	84
456	Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy. <b>2011</b> , 42, 3300-3		30
455	Pyroglutamate amyloid- $\beta$ (A $\beta$ ): a hatchet man in Alzheimer disease. <b>2011</b> , 286, 38825-32		146
454	In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 13110-7	6.6	256
453	Dynamic analysis of amyloid $\beta$ -protein in behaving mice reveals opposing changes in ISF versus parenchymal A $\beta$ during age-related plaque formation. <i>Journal of Neuroscience</i> , <b>2011</b> , 31, 15861-9	6.6	85
452	Abstracts of the Ninth International Symposium on Functional Neuroreceptor Mapping of the Living Brain. August 9-11, 2012. <b>2012</b> , 32 Suppl 1, S13-196		3
451	Biochemistry of amyloid $\beta$ -protein and amyloid deposits in Alzheimer disease. <b>2012</b> , 2, a006262		368
450	Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study. <b>2012</b> , 26, 50-4		9
449	Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. <b>2012</b> , 64, 27-81		66

448	Pyroglutamate amyloid $\beta$ (A $\beta$ ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. <b>2012</b> , 287, 8154-62		60
447	Chronic administration of an aglycosylated murine antibody of ponezumab does not worsen microhemorrhages in aged Tg2576 mice. <b>2012</b> , 9, 1059-68		16
446	Analysis of differential plaque depositions in the brains of Tg2576 and Tg-APPswe/PS1dE9 transgenic mouse models of Alzheimer disease. <b>2012</b> , 44, 492-502		22
445	Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-A $\beta$ APP mutation. <i>Translational Psychiatry</i> , <b>2012</b> , 2, e183	8.6	38
444	A $\beta$ 25-35/ERAGE interaction disrupts tight junctions of the blood-brain barrier via Ca $^{2+}$ -calcineurin signaling. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 8845-54	6.6	166
443	Improvements in a Mouse Model of Alzheimer's Disease Through SOD2 Overexpression are Due to Functional and Not Structural Alterations. <b>2012</b> , 5, 1-6		8
442	Neurologic and motor dysfunctions in APP transgenic mice. <b>2012</b> , 23, 363-79		36
441	Recognition memory and $\beta$ -amyloid plaques in adult Tg2576 mice are not modified after oral exposure to aluminum. <b>2012</b> , 26, 179-85		11
440	Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. <b>2012</b> , 69, 856-67		86
439	Proton and phosphorus magnetic resonance spectroscopy of a mouse model of Alzheimer's disease. <b>2012</b> , 31 Suppl 3, S87-99		31
438	Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease. <b>2012</b> , 118, 345-9		9
437	Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice. <b>2012</b> , 28, 567-78		44
436	Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease. <b>2012</b> , 34, 601-10		34
435	Longitudinal characterization of the brain proteomes for the tg2576 amyloid mouse model using shotgun based mass spectrometry. <b>2012</b> , 11, 6159-74		22
434	The complex PrP(c)-Fyn couples human oligomeric A $\beta$ with pathological tau changes in Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 16857-71a	6.6	216
433	Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. <b>2012</b> , 18, 1812-9		290
432	Decreased axonal transport rates in the Tg2576 APP transgenic mouse: improvement with the gamma-secretase inhibitor MRK-560 as detected by manganese-enhanced MRI. <b>2012</b> , 36, 3165-72		21
431	Activation of PPAR $\alpha$ prevents endothelial dysfunction induced by overexpression of amyloid- $\beta$ precursor protein. <b>2012</b> , 96, 504-12		23

430	Neurotoxicity of amyloid $\beta$ -protein: synaptic and network dysfunction. <b>2012</b> , 2, a006338	651
429	Reciprocal regulation of cholesterol and beta amyloid at the subcellular level in Alzheimer's disease. <b>2012</b> , 90, 753-64	15
428	Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. <b>2012</b> , 33, 933-44	61
427	Cognitive impairment and increased A $\beta$ levels induced by paraquat exposure are attenuated by enhanced removal of mitochondrial H(2)O(2). <b>2012</b> , 33, 432.e15-26	43
426	Plasma $\beta$ amyloid and the risk of Alzheimer's disease in Down syndrome. <b>2012</b> , 33, 1988-94	63
425	Berberine ameliorates $\beta$ -amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. <b>2012</b> , 33, 2903-19	176
424	Molecular imaging of dementia. <b>2012</b> , 12, 106-14	16
423	Studies of protein aggregation in A53T $\beta$ -synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. <b>2012</b> , 507, 137-42	5
422	Correlation of A $\beta$ deposition in the nasal cavity with the formation of senile plaques in the brain of a transgenic mouse model of Alzheimer's disease. <b>2012</b> , 513, 166-9	11
421	Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease. <b>2012</b> , 516, 232-6	11
420	LMN diet, rich in polyphenols and polyunsaturated fatty acids, improves mouse cognitive decline associated with aging and Alzheimer's disease. <b>2012</b> , 228, 261-71	40
419	Lidocaine attenuates cognitive impairment after isoflurane anesthesia in old rats. <b>2012</b> , 228, 319-27	70
418	Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. <i>Journal of Neuroinflammation</i> , <b>2012</b> , 9, 127	10.1 22
417	Cholinergic denervation exacerbates amyloid pathology and induces hippocampal atrophy in Tg2576 mice. <b>2012</b> , 48, 439-46	26
416	Intracellular amyloid- $\beta$ accumulation in calcium-binding protein-deficient neurons leads to amyloid- $\beta$ plaque formation in animal model of Alzheimer's disease. <b>2012</b> , 29, 615-28	47
415	Modulation of $\beta$ secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. <b>2012</b> , 7, 61	53
414	Transient pharmacologic lowering of A $\beta$ production prior to deposition results in sustained reduction of amyloid plaque pathology. <b>2012</b> , 7, 39	28
413	Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. <b>2012</b> , 7, 37	30

412	Overlapping profiles of A $\beta$ peptides in the Alzheimer's disease and pathological aging brains. <b>2012</b> , 4, 18	81
411	Toxoplasma gondii infection in the brain inhibits neuronal degeneration and learning and memory impairments in a murine model of Alzheimer's disease. <b>2012</b> , 7, e33312	54
410	Dynamin 1 regulates amyloid generation through modulation of BACE-1. <b>2012</b> , 7, e45033	19
409	Amyloid $\beta$ levels in human red blood cells. <b>2012</b> , 7, e49620	50
408	Wading pools, fading memories-place navigation in transgenic mouse models of Alzheimer's disease. <b>2012</b> , 4, 11	20
407	Acute blast injury reduces brain abeta in two rodent species. <b>2012</b> , 3, 177	29
406	Alzheimer's disease. 371-381	1
405	High-intensity physical activity modulates diet effects on cerebrospinal amyloid- $\beta$ levels in normal aging and mild cognitive impairment. <b>2012</b> , 28, 137-46	38
404	LRRTM3 is dispensable for amyloid- $\beta$ production in mice. <b>2012</b> , 31, 759-64	7
403	Reliable Measurements of the $\beta$ -Amyloid Pool in Blood Could Help in the Early Diagnosis of AD. <b>2012</b> , 2012, 604141	38
402	Mixed cerebrovascular disease and the future of stroke prevention. <b>2012</b> , 3, 39-51	28
401	Altered $\beta$ secretase activity in mild cognitive impairment and Alzheimer's disease. <b>2012</b> , 4, 344-52	48
400	Tannic acid is a natural $\beta$ secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. <b>2012</b> , 287, 6912-27	118
399	Midlife blood pressure, plasma $\beta$ -amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. <b>2012</b> , 59, 780-6	147
398	Novel Detox Gel Depot sequesters $\beta$ -Amyloid Peptides in a mouse model of Alzheimer's Disease. <b>2012</b> , 18, 99-106	12
397	Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina?. <b>2012</b> , 34, 633-49	63
396	Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. <b>2012</b> , 119, 843-50	43
395	Soluble A $\beta$ oligomer production and toxicity. <b>2012</b> , 120 Suppl 1, 125-139	276

394	The role of metallobiology and amyloid- $\beta$ peptides in Alzheimer's disease. <b>2012</b> , 120 Suppl 1, 149-166		198
393	The role of n-3 dietary polyunsaturated fatty acids in brain function and ameliorating Alzheimer's disease: Opportunities for biotechnology in the development of nutraceuticals. <b>2012</b> , 1, 159-166		12
392	APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD). <b>2012</b> , 36, 1357-75		43
391	Temporal course of cerebrospinal fluid dynamics and amyloid accumulation in the aging rat brain from three to thirty months. <b>2012</b> , 9, 3		56
390	The presence of A $\beta$ seeds, and not age per se, is critical to the initiation of A $\beta$ deposition in the brain. <i>Acta Neuropathologica</i> , <b>2012</b> , 123, 31-7	14.3	79
389	Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models. <b>2013</b> , 5, 19		23
388	AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 10075-84	6.6	36
387	Metabolic Syndrome. <b>2013</b> ,		24
386	3-Hydroxybutyrate methyl ester as a potential drug against Alzheimer's disease via mitochondria protection mechanism. <b>2013</b> , 34, 7552-62		84
385	Nonhuman amyloid oligomer epitope reduces Alzheimer's-like neuropathology in 3xTg-AD transgenic mice. <b>2013</b> , 48, 931-40		9
384	Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APP <sup>swe</sup> /PS1 <sup>dE9</sup> transgenic mice. <b>2013</b> , 19, 871-81		68
383	Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis. <b>2013</b> , 1832, 1437-48		26
382	N-truncated amyloid $\beta$ (A $\beta$ ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 189-205	14.3	123
381	Neuronal activity and secreted amyloid $\beta$ lead to altered amyloid $\beta$ precursor protein and presenilin 1 interactions. <b>2013</b> , 50, 127-34		22
380	Models of Alzheimer's Disease. <b>2013</b> , 595-632		
379	Proteopathic Seeds and Neurodegenerative Diseases. <b>2013</b> ,		4
378	Alzheimer's disease biomarkers: correspondence between human studies and animal models. <b>2013</b> , 56, 116-30		15
377	Proteases: Structure and Function. <b>2013</b> ,		25

376	PDK1 decreases TACE-mediated $\beta$ -secretase activity and promotes disease progression in prion and Alzheimer's diseases. <b>2013</b> , 19, 1124-31		78
375	ADAM10 missense mutations potentiate $\beta$ -amyloid accumulation by impairing prodomain chaperone function. <b>2013</b> , 80, 385-401		145
374	Changes in amyloid- $\beta$ and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. <b>2013</b> , 5, 194re2		125
373	Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. <b>2013</b> , 34, 169-83		58
372	Transient enriched housing before amyloidosis onset sustains cognitive improvement in Tg2576 mice. <b>2013</b> , 34, 211-25		48
371	Detecting spatial memory deficits beyond blindness in tg2576 Alzheimer mice. <b>2013</b> , 34, 716-30		38
370	Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2013</b> , 125, 187-99	14.3	58
369	Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 1651-9	6.6	154
368	Pyroglutamate-3 amyloid- $\beta$ deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. <b>2013</b> , 183, 369-81		84
367	Suspected limited efficacy of $\beta$ -secretase modulators. <b>2013</b> , 34, 1101-4		13
366	Cellular prion protein modulates $\beta$ -amyloid deposition in aged APP/PS1 transgenic mice. <b>2013</b> , 34, 2793-804		15
365	Disruption of neocortical histone H3 homeostasis by soluble A $\beta$ implications for Alzheimer's disease. <b>2013</b> , 34, 2081-90		41
364	Heterogeneity of elderly depression: increased risk of Alzheimer's disease and A $\beta$ protein metabolism. <b>2013</b> , 43, 203-8		30
363	Disease-modified glycogen synthase kinase-3 $\beta$ intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model. <b>2013</b> , 34, 1555-63		61
362	Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. <i>Journal of Neuroscience</i> , <b>2013</b> , 33, 3765-79	6.6	39
361	Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. <b>2013</b> , 15, 324-36		197
360	GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. <b>2013</b> , 78, 256-68		255
359	Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease. <b>2013</b> , 12, 116-40		34



358	New ELISAs with high specificity for soluble oligomers of amyloid $\beta$ -protein detect natural A $\beta$ oligomers in human brain but not CSF. <b>2013</b> , 9, 99-112	92
357	Long-term immunomodulatory effect of amniotic stem cells in an Alzheimer's disease model. <b>2013</b> , 34, 2408-20	111
356	Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble A $\beta$ 42 without affecting other A $\beta$ pools. <b>2013</b> , 125, 465-72	13
355	Early impairment in a water-finding test in a longitudinal study of the Tg2576 mouse model of Alzheimer's disease. <b>2013</b> , 1491, 117-26	16
354	Modeling of age-dependent amyloid accumulation and $\beta$ -secretase inhibition of soluble and insoluble A $\beta$ in a transgenic mouse model of amyloid deposition. <b>2013</b> , 1, e00012	3
353	The role of amyloid $\beta$ in the pathogenesis of Alzheimer's disease. <b>2013</b> , 66, 362-6	91
352	Disruption of blood-brain barrier in Alzheimer disease pathogenesis. <b>2013</b> , 1, e23993	56
351	Comment on "ApoE-directed therapeutics rapidly clear $\beta$ -amyloid and reverse deficits in AD mouse models". <b>2013</b> , 340, 924-d	108
350	Metabolism of amyloid $\beta$ peptide and pathogenesis of Alzheimer's disease. <b>2013</b> , 89, 321-39	31
349	Plasma amyloid- $\beta$ levels in drug-resistant bipolar depressed patients receiving electroconvulsive therapy. <b>2013</b> , 67, 185-91	11
348	Brain and circulating levels of A $\beta$ 1-40 differentially contribute to vasomotor dysfunction in the mouse brain. <b>2013</b> , 44, 198-204	42
347	CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice. <b>2013</b> , 124, 613-20	13
346	Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing A $\beta$ deposition and tau pathology in 3xTg-AD mice. <b>2013</b> , 126, 473-82	62
345	Reduction and the intracellular translocation of EphB2 in Tg2576 mice and the effects of $\beta$ -amyloid. <b>2013</b> , 39, 612-22	10
344	Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. <b>2013</b> , 110, 3089-94	85
343	Reduction of synaptojanin 1 accelerates A $\beta$ clearance and attenuates cognitive deterioration in an Alzheimer mouse model. <b>2013</b> , 288, 32050-63	48
342	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. <b>2013</b> , 18, 461-70	77
341	Optimized protocol for amyloid- $\beta$ extraction from the brain. <b>2013</b> , 34, 835-9	9

340	Early selective vulnerability of synapses and synaptic mitochondria in the hippocampal CA1 region of the Tg2576 mouse model of Alzheimer's disease. <b>2013</b> , 34, 887-96	38
339	Specific uptake of an amyloid- $\beta$ protofibril-binding antibody-tracer in A $\beta$ PP transgenic mouse brain. <b>2013</b> , 37, 29-40	43
338	An update of animal models of Alzheimer disease with a reevaluation of plaque depositions. <b>2013</b> , 22, 84-95	71
337	Investigation of nebivolol as a novel therapeutic agent for the treatment of Alzheimer's disease. <b>2013</b> , 33, 1147-56	18
336	CB $\beta$ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. <b>2013</b> , 19, 357-64	16
335	Accumulation of intraneuronal $\beta$ -amyloid 42 peptides is associated with early changes in microtubule-associated protein 2 in neurites and synapses. <b>2013</b> , 8, e51965	40
334	Vitamin D <sub>2</sub> -enriched button mushroom ( <i>Agaricus bisporus</i> ) improves memory in both wild type and APP <sup>swE/PS1dE9</sup> transgenic mice. <b>2013</b> , 8, e76362	36
333	Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review. <b>2013</b> , 5, 25	11
332	Increased efflux of amyloid- $\beta$ peptides through the blood-brain barrier by muscarinic acetylcholine receptor inhibition reduces pathological phenotypes in mouse models of brain amyloidosis. <b>2014</b> , 38, 767-86	11
331	Oxidative Changes and Possible Effects of Polymorphism of Antioxidant Enzymes in Neurodegenerative Disease. <b>2013</b> ,	1
330	Association between amylin and amyloid- $\beta$ peptides in plasma in the context of apolipoprotein E4 allele. <b>2014</b> , 9, e88063	13
329	Aggregate-depleted brain fails to induce A $\beta$ deposition in a mouse model of Alzheimer's disease. <b>2014</b> , 9, e89014	31
328	Spared piriform cortical single-unit odor processing and odor discrimination in the Tg2576 mouse model of Alzheimer's disease. <b>2014</b> , 9, e106431	12
327	Age-related changes of protein SUMOylation balance in the A $\beta$ PP Tg2576 mouse model of Alzheimer's disease. <b>2014</b> , 5, 63	35
326	CB <sub>2</sub> receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease. <b>2014</b> , 20, 29-36	39
325	Alzheimer's disease. 391-410	1
324	Parkin overexpression ameliorates hippocampal long-term potentiation and $\beta$ -amyloid load in an Alzheimer's disease mouse model. <b>2014</b> , 23, 1056-72	50
323	Neuritin can normalize neural deficits of Alzheimer's disease. <b>2014</b> , 5, e1523	21

322	β-Amyloid pathology alters neural network activation during retrieval of contextual fear memories in a mouse model of Alzheimer's disease. <b>2014</b> , 39, 1690-703		5
321	Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuro peptide Y neurons. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 9096-106	6.6	57
320	Anti-Aβ antibody target engagement: commentary regarding Watt et al. <i>Acta Neuropathol</i> 127:803-810 (2014). <i>Acta Neuropathologica</i> , <b>2014</b> , 128, 609-10	14.3	2
319	Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 7871-85	6.6	65
318	Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 11621-30	6.6	69
317	Cerebral amyloid angiopathy increases susceptibility to infarction after focal cerebral ischemia in Tg2576 mice. <b>2014</b> , 45, 3064-9		23
316	Chronic dietary supplementation of 4% figs on the modification of oxidative stress in Alzheimer's disease transgenic mouse model. <b>2014</b> , 2014, 546357		21
315	Qualification and application of a liquid chromatography-tandem mass spectrometric method for the determination of human Aβ1-40 and Aβ1-42 peptides in transgenic mouse plasma using micro-elution solid phase extraction. <b>2014</b> , 37, 636-44		3
314	Gastrodin alleviates memory deficits and reduces neuropathology in a mouse model of Alzheimer's disease. <b>2014</b> , 34, 370-7		51
313	Republished: the role of amyloid β in the pathogenesis of Alzheimer's disease. <b>2014</b> , 90, 113-7		11
312	Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia. <b>2014</b> , 171, 1210-30		99
311	1β25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer's disease. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 7091-101	6.6	96
310	Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling. <b>2014</b> , 79, 668-78		83
309	Comparative studies using the Morris water maze to assess spatial memory deficits in two transgenic mouse models of Alzheimer's disease. <b>2014</b> , 41, 798-806		25
308	Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice. <b>2014</b> , 289, 30303-30317		33
307	Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Aβ1-42 clearance. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 14484-501	6.6	70
306	MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research. <b>2014</b> , 37, 629-41		32
305	A genome-wide association meta-analysis of plasma Aβ peptides concentrations in the elderly. <b>2014</b> , 19, 1326-35		27

304	Insulin resistance in Alzheimer's disease. <b>2014</b> , 72 Pt A, 92-103		78
303	Mixed oligomers and monomeric amyloid- $\beta$ disrupts endothelial cells integrity and reduces monomeric amyloid- $\beta$ transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. <b>2014</b> , 1842, 1806-15		36
302	The association between caffeine and cognitive decline: examining alternative causal hypotheses. <b>2014</b> , 26, 581-90		11
301	Truncated and modified amyloid-beta species. <b>2014</b> , 6, 28		180
300	Focusing the amyloid cascade hypothesis on N-truncated A $\beta$ peptides as drug targets against Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2014</b> , 127, 787-801	14.3	99
299	Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer's disease by accelerating the clearance of amyloid-beta. <b>2014</b> , 8, 2345-59		134
298	Evidence for lymphatic A $\beta$ clearance in Alzheimer's transgenic mice. <b>2014</b> , 71, 215-9		38
297	Amyloid- $\beta$ (1-42) protofibrils stimulate a quantum of secreted IL-1 $\beta$ despite significant intracellular IL-1 $\beta$ accumulation in microglia. <b>2014</b> , 1842, 2276-85		22
296	Changes in the brain and plasma A $\beta$ peptide levels with age and its relationship with cognitive impairment in the APP <sup>swe</sup> /PS1 <sup>dE9</sup> mouse model of Alzheimer's disease. <b>2014</b> , 263, 269-79		28
295	PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. <b>2014</b> , 35, 2072-8		49
294	Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 7988-98	6.6	130
293	Mouse strain and brain region-specific expression of the glutaminyl cyclases QC and isoQC. <b>2014</b> , 36, 64-73		13
292	Defining the toxicology of aging. <b>2014</b> , 20, 375-84		35
291	Progress update: fluid and imaging biomarkers in Alzheimer's disease. <b>2014</b> , 75, 520-6		18
290	Impaired hippocampal acetylcholine release parallels spatial memory deficits in Tg2576 mice subjected to basal forebrain cholinergic degeneration. <b>2014</b> , 1543, 253-62		24
289	Botanics: a potential source of new therapies for Alzheimer's disease?. <b>2014</b> , 11		2
288	Pyroglutamate-modified amyloid- $\beta$ protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain. <b>2014</b> , 14, 53-66		26
287	Use of magnetization transfer contrast MRI to detect early molecular pathology in Alzheimer's disease. <b>2014</b> , 71, 333-8		17

286	Correlations of amyloid- $\beta$ concentrations between CSF and plasma in acute Alzheimer mouse model. <i>Scientific Reports</i> , <b>2014</b> , 4, 6777	4.9	30
285	Temporal changes of CD68 and $\alpha 7$ nicotinic acetylcholine receptor expression in microglia in Alzheimer's disease-like mouse models. <b>2015</b> , 44, 409-23		30
284	Peripheral amyloid levels present gender differences associated with aging in A $\beta$ PP/PS1 mice. <b>2015</b> , 44, 1063-8		28
283	Increased CSF A $\beta$ during the very early phase of cerebral A $\beta$ deposition in mouse models. <b>2015</b> , 7, 895-903		29
282	Arachidonic or Docosahexaenoic Acid Diet Prevents Memory Impairment in Tg2576 Mice. <b>2015</b> , 48, 149-62		25
281	A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer's disease. <b>2015</b> , 3, 2050312115598250		15
280	Diet rich in date palm fruits improves memory, learning and reduces beta amyloid in transgenic mouse model of Alzheimer's disease. <b>2015</b> , 6, 111-20		34
279	Environmental enrichment does not influence hypersynchronous network activity in the Tg2576 mouse model of Alzheimer's disease. <b>2015</b> , 7, 178		7
278	Early onset of hypersynchronous network activity and expression of a marker of chronic seizures in the Tg2576 mouse model of Alzheimer's disease. <b>2015</b> , 10, e0119910		40
277	Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer's Disease. <b>2015</b> , 10, e0136950		29
276	Oxidative Stress during the Progression of $\beta$ -Amyloid Pathology in the Neocortex of the Tg2576 Mouse Model of Alzheimer's Disease. <b>2015</b> , 2015, 967203		24
275	Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and A $\beta$ pathology and modulates A $\beta$ oligomerization. <b>2015</b> , 82, 552-560		36
274	Quaternary Structure Defines a Large Class of Amyloid- $\beta$ Oligomers Neutralized by Sequestration. <b>2015</b> , 11, 1760-71		106
273	$\beta$ -Hydroxybutyrate (Xyrem) ameliorates clinical symptoms and neuropathology in a mouse model of Alzheimer's disease. <b>2015</b> , 36, 832-44		28
272	Cross-talk between A $\beta$ and endothelial SSAO/VAP-1 accelerates vascular damage and A $\beta$ aggregation related to CAA-AD. <b>2015</b> , 36, 762-75		15
271	Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. <b>2015</b> , 112, E881-90		96
270	In vivo SPECT imaging of amyloid- $\beta$ deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease. <b>2015</b> , 56, 120-6		26
269	Reduction of p75 neurotrophin receptor ameliorates the cognitive deficits in a model of Alzheimer's disease. <b>2015</b> , 36, 740-52		20

268	Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. <b>2015</b> , 21, 880-6	354
267	Reelin protects against amyloid $\beta$ toxicity in vivo. <b>2015</b> , 8, ra67	62
266	Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family. <b>2015</b> , 84, 2266-73	23
265	The stress response neuropeptide CRF increases amyloid- $\beta$ production by regulating $\beta$ secretase activity. <b>2015</b> , 34, 1674-86	40
264	Neural stem cell transplantation at critical period improves learning and memory through restoring synaptic impairment in Alzheimer's disease mouse model. <b>2015</b> , 6, e1789	39
263	Inhibition of amyloid- $\beta$ plaque formation by $\beta$ synuclein. <b>2015</b> , 21, 802-7	74
262	Activation of mTOR: a culprit of Alzheimer's disease?. <b>2015</b> , 11, 1015-30	81
261	Arachidonic acid diet attenuates brain A $\beta$ deposition in Tg2576 mice. <b>2015</b> , 1613, 92-9	27
260	Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. <b>2015</b> , 42, 1119-32	81
259	Centrally Delivered BACE1 Inhibitor Activates Microglia, and Reverses Amyloid Pathology and Cognitive Deficit in Aged Tg2576 Mice. <i>Journal of Neuroscience</i> , <b>2015</b> , 35, 6931-6	6.6 20
258	Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. <i>Journal of Neuroscience</i> , <b>2015</b> , 35, 4857-68	6.6 99
257	Olfactory dysfunction: its early temporal relationship and neural correlates in the pathogenesis of Alzheimer's disease. <b>2015</b> , 122, 1475-97	38
256	Autoregulated paracellular clearance of amyloid- $\beta$ across the blood-brain barrier. <b>2015</b> , 1, e1500472	73
255	Brain-derived neurotrophic factor and TrkB expression in the "oldest-old," the 90+ Study: correlation with cognitive status and levels of soluble amyloid-beta. <b>2015</b> , 36, 3130-3139	30
254	Impact of peripheral myeloid cells on amyloid- $\beta$ pathology in Alzheimer's disease-like mice. <b>2015</b> , 212, 1811-8	79
253	Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis. <b>2015</b> , 112, 11965-70	87
252	Entorhinal cortical defects in Tg2576 mice are present as early as 2-4 months of age. <b>2015</b> , 36, 134-48	24
251	Combined treatment of amyloid- $\beta$ and $\beta$ stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSEN1 $\Delta$ E9 mice. <b>2015</b> , 36, 111-22	12

250	Age-associated evolution of plasmatic amyloid in mouse lemur primates: relationship with intracellular amyloid deposition. <b>2015</b> , 36, 149-56	12
249	P2Y receptors in Alzheimer's disease. <b>2015</b> , 107, 1-21	27
248	Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice. <b>2015</b> , 36, 201-10	52
247	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <b>2015</b> , 25, 401-8	115
246	Outstanding Phenotypic Differences in the Profile of Amyloid- $\beta$ between Tg2576 and APP <sup>swe</sup> /PS1 <sup>dE9</sup> Transgenic Mouse Models of Alzheimer's Disease. <b>2016</b> , 53, 773-85	9
245	Blood-based Amyloid and Tau Biomarker Tests For Alzheimer's Disease. <b>2016</b> , 4, 4-13	
244	Beneficial effect of diosgenin as a stimulator of NGF on the brain with neuronal damage induced by A $\beta$ 42 accumulation and neurotoxicant injection. <b>2016</b> , 32, 105-15	6
243	Mouse Genetic Models of Human Brain Disorders. <b>2016</b> , 7, 40	34
242	Glycines from the APP GXXXG/GXXXA Transmembrane Motifs Promote Formation of Pathogenic A $\beta$ Oligomers in Cells. <b>2016</b> , 8, 107	21
241	A Novel Form of Compensation in the Tg2576 Amyloid Mouse Model of Alzheimer's Disease. <b>2016</b> , 10, 152	3
240	A Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 Mice. <b>2016</b> , 11, e0147733	138
239	Assessing the Effects of Acute Amyloid $\beta$ Oligomer Exposure in the Rat. <b>2016</b> , 17,	10
238	Amyloid-associated depression and ApoE4 allele: longitudinal follow-up for the development of Alzheimer's disease. <b>2016</b> , 31, 316-22	22
237	Serum insulin-like growth factor-I and amyloid beta protein in Alzheimer's disease: relationship with cognitive function. <b>2016</b> , 16, 247-54	13
236	TrkB activation by 7, 8-dihydroxyflavone increases synapse AMPA subunits and ameliorates spatial memory deficits in a mouse model of Alzheimer's disease. <b>2016</b> , 136, 620-36	44
235	Immunotherapy targeting pyroglutamate-3 A $\beta$ prospects and challenges. <b>2016</b> , 11, 48	28
234	Overexpression of Metallothionein-1 Modulates the Phenotype of the Tg2576 Mouse Model of Alzheimer's Disease. <b>2016</b> , 51, 81-95	14
233	Alterations of the volatile metabolome in mouse models of Alzheimer's disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 19495	4.9 24

232	Increased A $\beta$ pathology in aged Tg2576 mice born to mothers fed a high fat diet. <i>Scientific Reports</i> , <b>2016</b> , 6, 21981	4.9	17
231	Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil. <i>Scientific Reports</i> , <b>2016</b> , 6, 34165	4.9	11
230	Interictal spikes during sleep are an early defect in the Tg2576 mouse model of $\beta$ -amyloid neuropathology. <i>Scientific Reports</i> , <b>2016</b> , 6, 20119	4.9	63
229	Dogs with Cognitive Dysfunction as a Spontaneous Model for Early Alzheimer's Disease: A Translational Study of Neuropathological and Inflammatory Markers. <b>2016</b> , 52, 433-49		43
228	Serum Levels of Albumin- $\beta$ Amyloid Complex in Patients with Depression. <b>2016</b> , 24, 764-72		3
227	Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. <b>2016</b> , 235, 34-47		766
226	Brain heterogeneity leads to differential innate immune responses and modulates pathogenesis of viral infections. <b>2016</b> , 30, 95-101		9
225	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\beta$ in a multicentre European memory clinic study. <b>2016</b> , 139, 2540-53		93
224	NPT088 reduces both amyloid- $\beta$ and tau pathologies in transgenic mice. <b>2016</b> , 2, 141-155		31
223	Epilepsy, amyloid- $\beta$ and D1 dopamine receptors: a possible pathogenetic link?. <b>2016</b> , 48, 161-171		48
222	Age-related synaptic dysfunction in Tg2576 mice starts as a failure in early long-term potentiation which develops into a full abolishment of late long-term potentiation. <b>2016</b> , 94, 266-81		5
221	Differential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor protein-specific antibodies. <b>2016</b> , 15, 953-63		17
220	Holdase activity of secreted Hsp70 masks amyloid- $\beta$ 42 neurotoxicity in <i>Drosophila</i> . <b>2016</b> , 113, E5212-21		46
219	Introduction to Alzheimer's Disease. <b>2016</b> , 73-98		1
218	AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease. <b>2017</b> , 55, 1039-1053		58
217	Immunotherapy Against N-Truncated Amyloid- $\beta$ Oligomers. <b>2016</b> , 37-50		3
216	The reemergence of long-term potentiation in aged Alzheimer's disease mouse model. <i>Scientific Reports</i> , <b>2016</b> , 6, 29152	4.9	19
215	AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. <b>2016</b> , 50, 1109-23		83



214	Brain Amyloid- $\beta$ Plays an Initiating Role in the Pathophysiological Process of the PS1V97L-Tg Mouse Model of Alzheimer's Disease. <b>2016</b> , 52, 1089-99	8
213	Dementia-linked amyloidosis is associated with brain protein deamidation as revealed by proteomic profiling of human brain tissues. <b>2016</b> , 9, 20	25
212	Tooth loss might not alter molecular pathogenesis in an aged transgenic Alzheimer's disease model mouse. <b>2016</b> , 33, 308-14	16
211	Vascular cognitive impairment and dementia. <b>2016</b> , 1862, 860-8	76
210	Amyloid- $\beta$ dimers in the absence of plaque pathology impair learning and synaptic plasticity. <b>2016</b> , 139, 509-25	54
209	Dietary DHA supplementation causes selective changes in phospholipids from different brain regions in both wild type mice and the Tg2576 mouse model of Alzheimer's disease. <b>2016</b> , 1861, 524-37	42
208	Overexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmission. <b>2016</b> , 4, e12665	9
207	Brain ischemia with Alzheimer phenotype dysregulates Alzheimer's disease-related proteins. <b>2016</b> , 68, 582-91	17
206	Neuregulin-1 attenuates cognitive function impairments in a transgenic mouse model of Alzheimer's disease. <b>2016</b> , 7, e2117	32
205	Enhanced Detection Specificity and Sensitivity of Alzheimer's Disease Using Amyloid- $\beta$ -Targeted Quantum Dots. <b>2016</b> , 27, 809-14	14
204	X-ray Crystallographic Structures of a Trimer, Dodecamer, and Annular Pore Formed by an A $\beta$ 17-36 $\beta$ -Hairpin. <b>2016</b> , 138, 4634-42	54
203	Amyloid $\beta$ -interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets. <b>2016</b> , 137, 17-38	51
202	Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer's disease. <b>2016</b> , 19, 475-483	24
201	Hypertension enhances A $\beta$ -induced neurovascular dysfunction, promotes $\beta$ -secretase activity, and leads to amyloidogenic processing of APP. <b>2016</b> , 36, 241-52	97
200	Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid- $\beta$ Protein Precursor Transgenic Mice. <b>2017</b> , 56, 743-761	22
199	Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of $\beta$ -Amyloid in an Animal Model of Alzheimer's Disease. <b>2017</b> , 25, 153-164	10
198	Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits. <b>2017</b> , 1863, 991-1001	38
197	An amylin analog used as a challenge test for Alzheimer's disease. <b>2017</b> , 3, 33-43	10

196	Memantine reduces the production of amyloid- $\beta$ peptides through modulation of amyloid precursor protein trafficking. <b>2017</b> , 798, 16-25		22
195	Brain and Brown Adipose Tissue Metabolism in Transgenic Tg2576 Mice Models of Alzheimer Disease Assessed Using F-FDG PET Imaging. <b>2017</b> , 16, 1536012117704557		16
194	Paternal spatial training enhances offspring's cognitive performance and synaptic plasticity in wild-type but not improve memory deficit in Alzheimer's mice. <i>Scientific Reports</i> , <b>2017</b> , 7, 1521	4.9	8
193	View-aligned hypergraph learning for Alzheimer's disease diagnosis with incomplete multi-modality data. <b>2017</b> , 36, 123-134		82
192	BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A $\beta$ Peptides. <b>2017</b> , 57, 1460-1471		32
191	A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment. <b>2017</b> , 77, 92-105		10
190	Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium. <b>2017</b> , 32, 20-32		22
189	An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. <b>2017</b> , 9, 703-715		39
188	Reverse Expression of Aging-Associated Molecules through Transfection of miRNAs to Aged Mice. <b>2017</b> , 6, 106-115		15
187	Worsening of memory deficit induced by energy-dense diet in a rat model of early-Alzheimer's disease is associated to neurotoxic A $\beta$ species and independent of neuroinflammation. <b>2017</b> , 1863, 731-743		22
186	Design and Application of Anti-Amyloid Peptide-Based Inhibitors as a Therapeutic Strategy of Alzheimer's Disease. <b>2017</b> , 73-111		1
185	Plasma Amyloid- $\beta$ Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. <b>2017</b> , 60, 977-987		26
184	Cerebrospinal Fluid Amyloid- $\beta$ 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease. <b>2017</b> , 60, 183-200		25
183	SEN1500, a novel oral amyloid- $\beta$ aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer's disease. <b>2017</b> , 660, 96-102		2
182	Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease. <b>2017</b> , 43, 553-570		35
181	ApoE4-associated phospholipid dysregulation contributes to development of Tau hyper-phosphorylation after traumatic brain injury. <i>Scientific Reports</i> , <b>2017</b> , 7, 11372	4.9	33
180	A modified formulation of Huanglian-Jie-Du-Tang reduces memory impairments and $\beta$ -amyloid plaques in a triple transgenic mouse model of Alzheimer's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 6238	4.9	21
179	Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 12263-12271	6.6	28

178	Near infrared light decreases synaptic vulnerability to amyloid beta oligomers. <i>Scientific Reports</i> , <b>2017</b> , 7, 15012	4.9	25
177	Animal Models of Alzheimer’s Disease. <b>2017</b> , 1031-1085		9
176	Aβ seeding potency peaks in the early stages of cerebral β-amyloidosis. <b>2017</b> , 18, 1536-1544		25
175	A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation. <i>Journal of Neuroinflammation</i> , <b>2017</b> , 14, 128	10.1	34
174	Immunoproteasome deficiency alters microglial cytokine response and improves cognitive deficits in Alzheimer’s disease-like APPS1 mice. <b>2017</b> , 5, 52		30
173	Compilation and Analysis of Enzymes, Engineered Antibodies, and Nanoparticles Designed to Interfere with Amyloid-β Aggregation. <b>2017</b> , 57, 622-633		1
172	Alzheimer’s Disease. <b>2017</b> , 83-118		1
171	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer’s disease. <b>2017</b> , 140, 3301-3316		10
170	Methods to Study Changes in Inherent Protein Aggregation with Age in <i>Caenorhabditis elegans</i> . <b>2017</b> ,		3
169	Luteolin Inhibits Fibrillary β-Amyloid-Induced Inflammation in a Human Blood-Brain Barrier Model by Suppressing the p38 MAPK-Mediated NF-κB Signaling Pathways. <b>2017</b> , 22,		51
168	Influence of Transgenic Metallothionein-1 on Gliosis, CA1 Neuronal Loss, and Brain Metal Levels of the Tg2576 Mouse Model of Alzheimer’s Disease. <b>2017</b> , 18,		7
167	YXQN Reduces Alzheimer’s Disease-Like Pathology and Cognitive Decline in APPswePS1dE9 Transgenic Mice. <b>2017</b> , 9, 157		13
166	Progranulin gene delivery reduces plaque burden and synaptic atrophy in a mouse model of Alzheimer’s disease. <b>2017</b> , 12, e0182896		25
165	Effects of aquatic and land-based exercises on amyloid beta, heat shock protein 27, and pulse wave velocity in elderly women. <b>2018</b> , 108, 62-68		7
164	Early alteration of distribution and activity of hippocampal type-1 cannabinoid receptor in Alzheimer’s disease-like mice overexpressing the human mutant amyloid precursor protein. <b>2018</b> , 130, 366-373		14
163	Targeting Insulin for Alzheimer’s Disease: Mechanisms, Status and Potential Directions. <b>2018</b> , 64, S427-S453		14
162	β-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects. <b>2018</b> , 55, 2653-2675		23
161	Multi-Hypergraph Learning for Incomplete Multimodality Data. <b>2018</b> , 22, 1197-1208		22

160	Glucocorticoid may influence amyloid $\beta$ metabolism in patients with depression. <b>2018</b> , 259, 191-196	16
159	Amylin in Alzheimer's disease: Pathological peptide or potential treatment?. <b>2018</b> , 136, 287-297	13
158	Short A $\beta$ peptides attenuate A $\beta$ 2 toxicity in vivo. <b>2018</b> , 215, 283-301	33
157	Alzheimer's disease as oligomeropathy. <b>2018</b> , 119, 57-70	67
156	NGF-Dependent Changes in Ubiquitin Homeostasis Trigger Early Cholinergic Degeneration in Cellular and Animal AD-Model. <b>2018</b> , 12, 487	9
155	Multifunctional Nanoparticles for Successful Targeted Drug Delivery across the Blood-Brain Barrier. <b>2018</b> ,	6
154	Passive A $\beta$ Immunotherapy: Current Achievements and Future Perspectives. <b>2018</b> , 23,	29
153	Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease. <b>2018</b> , 62, 597-609	1
152	Modeling amyloid beta and tau pathology in human cerebral organoids. <b>2018</b> , 23, 2363-2374	154
151	Multimodal Chemical Imaging of Amyloid Plaque Polymorphism Reveals A $\beta$ Aggregation Dependent Anionic Lipid Accumulations and Metabolism. <b>2018</b> , 90, 8130-8138	24
150	The Level of Plasma Amyloid- $\beta$ 40 Is Correlated with Peripheral Transport Proteins in Cognitively Normal Adults: A Population-Based Cross-Sectional Study. <b>2018</b> , 65, 951-961	8
149	Defensive effect of microRNA-200b/c against amyloid-beta peptide-induced toxicity in Alzheimer's disease models. <b>2018</b> , 13, e0196929	48
148	Plasma amyloid- $\beta$ levels, cerebral atrophy and risk of dementia: a population-based study. <b>2018</b> , 10, 63	25
147	Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-A $\beta$ Formation. <b>2018</b> , 23,	8
146	Retinol-Binding Protein Interferes with Transthyretin-Mediated $\beta$ -Amyloid Aggregation Inhibition. <b>2018</b> , 57, 5029-5040	5
145	Disaggregation of A $\beta$ 2 for Structural and Biochemical Studies. <b>2018</b> , 1777, 321-330	1
144	Walnut Supplementation in the Diet Reduces Oxidative Damage and Improves Antioxidant Status in Transgenic Mouse Model of Alzheimer's Disease. <b>2018</b> , 64, 1295-1305	21
143	Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 919-938	14.3 19

142	Targeted Lipidomics Investigation of N-acylethanolamines in a Transgenic Mouse Model of AD: A Longitudinal Study. <b>2019</b> , 121, 1900015		0
141	Effects of Dabigatran in Mouse Models of Aging and Cerebral Amyloid Angiopathy. <b>2019</b> , 10, 966		9
140	Transplantation of Mesenchymal Stem Cells Improves Amyloid- $\beta$ Pathology by Modifying Microglial Function and Suppressing Oxidative Stress. <b>2019</b> , 72, 867-884		19
139	Age-Related Changes of the Neurovascular Unit in the Cerebral Cortex of Alzheimer Disease Mouse Models: A Neuroanatomical and Molecular Study. <b>2019</b> , 78, 101-112		9
138	Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer's Disease. <b>2019</b> , 3, 77-94		2
137	Heterochromatic genome instability and neurodegeneration sharing similarities with Alzheimer's disease in old Bmi1 $\pm$ mice. <i>Scientific Reports</i> , <b>2019</b> , 9, 594	4.9	13
136	Oral Immunization with Soybean Storage Protein Containing Amyloid- $\beta$ 4-10 Prevents Spatial Learning Decline. <b>2019</b> , 70, 487-503		2
135	Potential Value of Plasma Amyloid- $\beta$ , Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease. <b>2019</b> , 10, 3479-3485		26
134	Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer's disease. <b>2019</b> , 7, 79		4
133	Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. <b>2019</b> , 127, 605-615		39
132	Cell Type-Specific Human APP Transgene Expression by Hippocampal Interneurons in the Tg2576 Mouse Model of Alzheimer's Disease. <b>2019</b> , 13, 137		2
131	Nanowired delivery of cerebrolysin with neprilysin and p-Tau antibodies induces superior neuroprotection in Alzheimer's disease. <b>2019</b> , 245, 145-200		17
130	The Amazon rain forest plant <i>Uncaria tomentosa</i> (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. <i>Scientific Reports</i> , <b>2019</b> , 9, 561	4.9	23
129	Pyroglutamation of amyloid- $\beta$ x-42 (A $\beta$ x-42) followed by A $\beta$ 1-40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology. <b>2019</b> , 294, 6719-6732		30
128	What's New on Alzheimer's Disease? Insights From AD Mouse Models. <b>2019</b> , 431-431		0
127	Assessment of diets containing curcumin, epigallocatechin-3-gallate, docosahexaenoic acid and lipoic acid on amyloid load and inflammation in a male transgenic mouse model of Alzheimer's disease: Are combinations more effective?. <b>2019</b> , 124, 505-519		25
126	Beclin1-driven autophagy modulates the inflammatory response of microglia via NLRP3. <b>2019</b> , 38,		86
125	Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice. <b>2019</b> , 294, 2714-2731		44

124	Defined astrocytic expression of human amyloid precursor protein in Tg2576 mouse brain. <b>2019</b> , 67, 393-403		9
123	GM1 locates to mature amyloid structures implicating a prominent role for glycolipid-protein interactions in Alzheimer pathology. <b>2019</b> , 1867, 458-467		19
122	Animal Models of Psychosis in Alzheimer Disease. <b>2020</b> , 28, 1-19		7
121	Beta-Amyloid Increases the Expression Levels of Tid1 Responsible for Neuronal Cell Death and Amyloid Beta Production. <b>2020</b> , 57, 1099-1114		5
120	Chemical imaging of evolving amyloid plaque pathology and associated A $\beta$ peptide aggregation in a transgenic mouse model of Alzheimer's disease. <b>2020</b> , 152, 602-616		8
119	Serum levels and mutual correlations of amyloid $\beta$ in patients with depression. <b>2020</b> , 20, 125-129		3
118	14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , <b>2020</b> , 40, 8188-8203	6.6	5
117	Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. <b>2020</b> , 12, 272		3
116	Interleukin-12/23 deficiency differentially affects pathology in male and female Alzheimer's disease-like mice. <b>2020</b> , 21, e48530		11
115	Higher Plasma Amyloid- $\beta$ Levels Are Associated with a Higher Risk of Cancer: A Population-Based Prospective Cohort Study. <b>2020</b> , 29, 1993-2001		0
114	Gallic acid is a dual $\beta$ -secretase modulator that reverses cognitive impairment and remediates pathology in Alzheimer mice. <b>2020</b> , 295, 16251-16266		15
113	Metabolic Profiling of Female Tg2576 Mouse Brains Provides Novel Evidence Supporting Intranasal Low-Dose Pioglitazone for Long-Term Treatment at an Early Stage of Alzheimer's Disease. <b>2020</b> , 8,		6
112	Advancements in the Blood-Brain Barrier Penetrating Nanoplatfoms for Brain Related Disease Diagnostics and Therapeutic Applications. <b>2020</b> , 12,		17
111	Infusion of blood from mice displaying cerebral amyloidosis accelerates amyloid pathology in animal models of Alzheimer's disease. <b>2020</b> , 8, 213		4
110	Urokinase-Type Plasminogen Activator Protects Cerebral Cortical Neurons from Soluble A $\beta$ -Induced Synaptic Damage. <i>Journal of Neuroscience</i> , <b>2020</b> , 40, 4251-4263	6.6	8
109	Therapeutic modulators of the serotonin 5-HT receptor: a patent review (2014-present). <b>2020</b> , 30, 495-508		5
108	Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. <b>2020</b> , 21,		4
107	MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer's disease pathogenesis. <b>2021</b> , 26, 4687-4701		13

106	Age-Specific Retinal and Cerebral Immunodetection of Amyloid- $\beta$ Plaques and Oligomers in a Rodent Model of Alzheimer's Disease. <b>2020</b> , 76, 1135-1150	18
105	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. <b>2020</b> , 49, 5446-5472	25
104	Effects of neural stem cell transplantation in Alzheimer's disease models. <b>2020</b> , 27, 29	29
103	Therapeutic Effects of Human Amniotic Epithelial Stem Cells in a Transgenic Mouse Model of Alzheimer's Disease. <b>2020</b> , 21,	12
102	Diversity in A $\beta$ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis. <b>2020</b> , 8, 43	6
101	Islet Amyloid Polypeptide: A Partner in Crime With A $\beta$ in the Pathology of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , <b>2020</b> , 13, 35	6.1 19
100	Low-Dose Phosphodiesterase III Inhibitor Reduces the Vascular Amyloid Burden in Amyloid- $\beta$ Protein Precursor Transgenic Mice. <b>2020</b> , 21,	3
99	The interaction of insoluble Amyloid- $\beta$ with soluble Amyloid- $\beta$ dimers decreases Amyloid- $\beta$ plaque numbers. <b>2021</b> , 47, 603-610	2
98	Leucine Carboxyl Methyltransferase 1 Overexpression Protects Against Cognitive and Electrophysiological Impairments in Tg2576 APP Transgenic Mice. <b>2021</b> , 79, 1813-1829	1
97	Stem Cell Therapies in Alzheimer's Disease: Applications for Disease Modeling. <b>2021</b> , 377, 207-217	7
96	Insoluble Vascular Amyloid Deposits Trigger Disruption of the Neurovascular Unit in Alzheimer's Disease Brains. <b>2021</b> , 22,	6
95	Early changes in synaptic and intrinsic properties of dentate gyrus granule cells in a mouse model of Alzheimer's disease neuropathology and atypical effects of the cholinergic antagonist atropine. <b>2021</b> , 152, 105274	1
94	Transmission of cerebral amyloid pathology by peripheral administration of misfolded A $\beta$ aggregates. <b>2021</b> ,	5
93	A high-fat diet exacerbates the Alzheimer's disease pathology in the hippocampus of the App knock-in mouse model. <b>2021</b> , 20, e13429	3
92	N-Truncated A $\beta$ Starting at Position Four-Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer's Disease. <b>2021</b> , 13, 710579	4
91	Immunohistochemical Study of ASC Expression and Distribution in the Hippocampus of an Aged Murine Model of Alzheimer's Disease. <b>2021</b> , 22,	0
90	Repetitive Low-Level Blast Exposure Improves Behavioral Deficits and Chronically Lowers A $\beta$ 42 in an Alzheimer Disease Transgenic Mouse Model. <b>2021</b> , 38, 3146-3173	4
89	Qingyangshen mitigates amyloid- $\beta$ and Tau aggregate defects involving PPAR $\beta$ /FEB activation in transgenic mice of Alzheimer's disease. <b>2021</b> , 91, 153648	7

88	Development of a Plasma Biomarker Diagnostic Model Incorporating Ultrasensitive Digital Immunoassay as a Screening Strategy for Alzheimer Disease in a Chinese Population. <b>2021</b> , 67, 1628-1639	2
87	Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand. <b>2021</b> , 17, 60	0
86	Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPAR $\alpha$ agonism in an Alzheimer's mouse model. <b>2021</b> , 11, e01973	7
85	Understanding and Treating Alzheimer's Disease. <b>2006</b> , 49-70	1
84	Alzheimer's Disease as a Proteolytic Disorder. <b>2002</b> , 7-12	1
83	A $\beta$ Degradation. <b>2007</b> , 157-178	1
82	Role of A $\beta$ Transport and Clearance in the Pathogenesis and Treatment of Alzheimer's Disease. <b>2007</b> , 179-198	5
81	Cognitive Impairment in Transgenic A $\beta$ and Tau Models of Alzheimer's Disease. <b>2007</b> , 77-91	1
80	Metabolic Syndrome as a Risk Factor for Alzheimer Disease. <b>2013</b> , 281-341	3
79	APP-Based Transgenic Models: The Tg2576 Model. <b>2011</b> , 387-398	2
78	Imaging in Neurology Research II: PET Imaging of CNS Disorders. <b>2011</b> , 499-513	3
77	Origin(s) of Intraneuronal Amyloid. <b>2016</b> , 15-41	1
76	Serum insulin-like growth factor I regulates brain amyloid- $\beta$ levels.	90
75	Anti-A $\beta$ 42- and anti-A $\beta$ 40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. <b>2006</b> , 116, 193-201	155
74	S100a9 knockdown decreases the memory impairment and the neuropathology in Tg2576 mice, AD animal model. <b>2010</b> , 5, e8840	63
73	Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease. <b>2010</b> , 5, e10561	52
72	Behavioral defects in chaperone-deficient Alzheimer's disease model mice. <b>2011</b> , 6, e16550	28
71	Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. <b>2012</b> , 7, e32737	176



70	The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer's disease mice. <b>2012</b> , 7, e45757	107
69	Sex-dependent alterations in social behaviour and cortical synaptic activity coincide at different ages in a model of Alzheimer's disease. <b>2012</b> , 7, e46111	42
68	Ferulic acid is a nutraceutical $\beta$ -secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. <b>2013</b> , 8, e55774	118
67	Modifications of hippocampal circuits and early disruption of adult neurogenesis in the tg2576 mouse model of Alzheimer's disease. <b>2013</b> , 8, e76497	58
66	$\alpha$ 7 Nicotinic receptor-mediated astrocytic gliotransmitter release: $\alpha$ 7 effects in a preclinical Alzheimer's mouse model. <b>2013</b> , 8, e81828	61
65	S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model. <b>2014</b> , 9, e88924	25
64	A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. <b>2014</b> , 9, e102136	55
63	Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. <b>2015</b> , 10, e0116678	44
62	Long-term dietary supplementation of pomegranates, figs and dates alleviate neuroinflammation in a transgenic mouse model of Alzheimer's disease. <b>2015</b> , 10, e0120964	51
61	Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme. <b>2015</b> , 10, e0143518	13
60	Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid- $\beta$ or Pathologic Phenotype. <b>2016</b> , 11, e0159119	7
59	Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. <b>2018</b> , 9, 5614-5626	8
58	A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid $\beta$ -Peptide from the Brain. <b>2016</b> , 13, 615-20	49
57	The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. <b>2004</b> , 1, 121-5	131
56	Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer's Disease Immunotherapy. <b>2013</b> , 11, 491-8	41
55	Toxic oligomer species of amyloid- $\beta$ in Alzheimer's disease, a timing issue. <b>2014</b> , 144, w14021	24
54	Revisiting the dilution factor as vital parameter for sensitivity of ELISA assay in CSF and Plasma. <b>2015</b> , 22, 37-42	4
53	Nutritional Antioxidant Enrichment and Improved Cognitive Function in Canines. <b>2005</b> , 213-223	

52	Actions of Bioactive Phytochemicals in Cell Function and Alzheimer's Disease Pathology. <b>2009</b> ,	1
51	Proteases in the Nervous System. <b>2013</b> , 319-371	1
50	Amyloid- $\beta$ Transmissibility. <b>2013</b> , 71-86	
49	Melatonin in Alzheimer's Disease: Focus on Neuroprotective Role. <b>2014</b> , 235-247	
48	p75NTR: A Molecule with Multiple Functions in Amyloid-Beta Metabolism and Neurotoxicity. <b>2014</b> , 1925-1944	
47	Molecular, Cellular, and Animal Experiments in Formaldehyde Study. <b>2017</b> , 245-270	
46	Serum-dependent and independent regulation of PARP2.	
45	A Comparative Study of [F-18] Florbetaben (FBB) PET Imaging, Pathology, and Cognition between Normal and Alzheimer Transgenic Mice. <b>2019</b> , 25, 7-14	
44	Natural age-related sleep-wake alterations onset prematurely in the Tg2576 mouse model of Alzheimer's disease.	0
43	The autophagy activator Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer's disease mouse model.	
42	The autophagy activator Spermidine ameliorates Alzheimer's disease pathology and neuroinflammation in mice.	0
41	Physiologic and Neurotoxic Properties of A $\beta$ Peptides. <b>2007</b> , 179-197	
40	Early changes in synaptic and intrinsic properties of dentate gyrus granule cells in a mouse model of Alzheimer's disease neuropathology and atypical effects of the cholinergic antagonist atropine.	
39	Expression of the neuronal adaptor protein X11alpha protects against memory dysfunction in a transgenic mouse model of Alzheimer's disease. <b>2010</b> , 20, 31-6	6
38	Alzheimer's disease biomarkers in animal models: closing the translational gap. <b>2013</b> , 2, 108-20	13
37	Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro. <b>2021</b> , 9, 188	3
36	Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.. <b>2022</b> , 234, 108119	5
35	Glucosylceramide synthase inhibition reduces ganglioside GM3 accumulation, alleviates amyloid neuropathology, and stabilizes remote contextual memory in a mouse model of Alzheimer's disease.. <b>2022</b> , 14, 19	0

34	Robust structural color beads by self-adhesion amorphous colloidal particles for detection of cerebrospinal fluid biomarkers. <b>2022</b> , 434, 134657		0
33	Alzheimer's disease amyloid- $\beta$ pathology in the lens of the eye.. <b>2022</b> , 108974		1
32	Impact of Caffeine on Alzheimer's Disease Pathogenesis-Protective or Risk Factor?. <b>2022</b> , 12,		1
31	Intracerebral Infection with Impairs Spatial Learning and Induces Necrosis of Hippocampal Neurons in the Tg2576 Mouse Model of Alzheimer's Disease.. <b>2022</b> , 6, 101-114		
30	Longitudinal assessment of aggression and circadian rhythms in the APPswe mouse model of Alzheimer's disease.. <b>2022</b> , 113787		0
29	Lipid Rafts Act as a Common Platform for Amyloid- $\beta$ Oligomer-Induced Alzheimer's Disease Pathology.. <b>2022</b> ,		0
28	Image_1.TIF. <b>2018</b> ,		
27	Image_2.TIF. <b>2018</b> ,		
26	Image_3.TIF. <b>2018</b> ,		
25	Image_4.TIF. <b>2018</b> ,		
24	Image_5.TIF. <b>2018</b> ,		
23	Image_6.TIF. <b>2018</b> ,		
22	Models of cerebral amyloid angiopathy-related intracerebral hemorrhage. <b>2022</b> ,		
21	MRTF-A-mediated protection against amyloid- $\beta$ -induced neuronal injury correlates with restoring autophagy via miR-1273g-3p/mTOR axis in Alzheimer models.		1
20	Isotope-labeled amyloid- $\beta$ does not transmit to the brain in a prion-like manner after peripheral administration.		1
19	The Systemic Effects of Exercise on the Systemic Effects of Alzheimer's Disease. <i>Antioxidants</i> , <b>2022</b> , 11, 1028	7.1	1
18	Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of A $\beta$ in neurons, yielding senile plaques. <i>Nature Neuroscience</i> ,	25.5	13
17	Mouse Models of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 15,	6.1	1

16	Spermidine reduces neuroinflammation and soluble amyloid beta in an Alzheimer's disease mouse model. <i>Journal of Neuroinflammation</i> , <b>2022</b> , 19,	10.1	2
15	Blood-based A $\beta$ 42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention. <i>Acta Neuropathologica</i> ,	14.3	1
14	Alzheimer diseases. <b>2023</b> , 313-336		0
13	The effect of dietary fat consumption on Alzheimer's disease pathogenesis in mouse models. <i>Translational Psychiatry</i> , <b>2022</b> , 12,	8.6	0
12	Sustained high body temperature exacerbates cognitive function and Alzheimer's disease-related pathologies. <i>Scientific Reports</i> , <b>2022</b> , 12,	4.9	1
11	Sex Differences in Hypothalamic Changes and the Metabolic Response of TgAPP Mice to a High Fat Diet. 16,		0
10	The Role of Amyloid- $\beta$ , Tau, and $\alpha$ Synuclein Proteins as Putative Blood Biomarkers in Patients with Cerebral Amyloid Angiopathy. <b>2022</b> , 1-11		
9	Clinical course and serum amyloid $\beta$ levels in elderly patients with major depressive disorder. <b>2022</b> , 315, 156-161		
8	The Role of Circulating A $\beta$ Seeds in the Progression of Cerebral Amyloidosis. <b>2022</b> , 17, 263310552211230		0
7	Effects of Simvastatin on Plasma Amyloid- $\beta$ Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. <b>2022</b> , 1-14		0
6	The Effects of Spirulina maxima Extract on Memory Improvement in Those with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <b>2022</b> , 14, 3714		0
5	A Biodistribution Study of the Radiolabeled Kv1.3-Blocking Peptide DOTA-HsTX1[R14A] Demonstrates Brain Uptake in a Mouse Model of Neuroinflammation.		0
4	The Effects of Dietary Interventions on Brain Aging and Neurological Diseases. <b>2022</b> , 14, 5086		0
3	Animal Models of Amyloid/PS-1 Pathology. <b>2011</b> , 15-38		0
2	Deletion of UCP1 in Tg2576 Mice Increases Body Temperature and Exacerbates Alzheimer's Disease-Related Pathologies. <b>2023</b> , 24, 2741		0
1	Cerebral A $\beta$ deposition precedes reduced cerebrospinal fluid and serum A $\beta$ 42/A $\beta$ 40 ratios in the AppNL $\Delta$ E/NL $\Delta$ E knock-in mouse model of Alzheimer's disease. <b>2023</b> , 15,		0